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GUIDELINES
he purpose of the UWO Medical Journa l is to
provide a ingle forum for original articles based on
clinical or research medicine of topical or historical
interes t. Since readers hip of the Journ a l is
interdisciplinary, articles published w ill attempt to reflect
a wide range of medical interests. In this r e gard,
submissions hould be directed towards the ge neral
medical reader. Articles which do not pertain to the
feature topic will be given lower priority as will those with
excessive technical jargon. Please restrict submissions to
under 2,000 words.
Informal peer review is required, i.e., non-specialist
authors are encouraged to collaborate with, or at
minimum, have their work reviewed for conten t by a
pecialist in the field . This individual, if not a co-author, is
to be acknowledged at the end of the paper. In addition, it
is recommended that all submissions be proof-read for
significant stylistic or grammatical error . The editors will
not ass ume re ponsibility for correction of this nature
and articles requiring such revisions will be returned to
the author.
Submissions are to include a cover letter, two double
spaced paper copies, and the full text on 3.5" computer
diskette in Microsoft Word or WordPerfect form a t. The
cover letter should be signed by all authors and indicate
that the manuscript has not been published previously.
Figures s hould b e profes sionall y d r awn;
photocopy ing of illus trations from texts, without the
permission of the publi her, is copyright infringement.
Figures and tables should each be submitted on a sep arate
page and any illustration with a grey-scale should be in
the form of a photograph. Two copies of figures or tables
should be included with labels on the back indicating
number as well as the first author. Legends, which are to
be included at the end of the text, should star t on a
separate page with arabic numerals corresponding to the
figures and tables.
Submis ions and disk become the property of the
Journal. The Journal reserves the right to correct errors of
punctuation and spelling. Short biographical notes on the
authors are to be included at the beginning of each paper.
Affiliation with UWO is not a prerequisite for authorship.

T

The U. W.O. Medical Journal is an interdisciplinary
medical science publication, established in 1930. The
Journal is published twice each academic year: Winter,
& Spring. Subscription is $17.00 per year. © All
material published in the U. W.O. Medical Journal is
copywright protected-no section of the U. W.O.
Medical Journal may be reproduced withou t the
expressed written permission of the Editor.
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References are indicated numerically in the text 1 and
listed a endnote in order of appearance. 2 Do not use
the 'endnote' feature of your word processing program;
list references as part of the text on a separate page
immediately following the bod y of the docum e nt .
Punc tuation come before reference numbers and
sentences are separated by one space only. Examples of
Journal reference format follow below:
1. Douglas J, Tlronras S, jan MA . Clinical value of polysonmograplry .
l.mrcet1992; 339(2):347-50.
2. Dement WC, Car kndon MA , Richardson G. Excessive daytime slee11iness
in /Ire sleep apnea syndrome. In: Guilleminau/1 C, Dement WC, eds. Sleep

Apnea Syndromes. New York: Alan R Liss, 1978:23-46.

Plea e direct submissions, including return address,
phone and fa x number, to : UWO Medical Journal,
Health Science Building, University of Western
Ontario, London, Ontario, 6A 5Cl. Tel: (519) 661-2076.
Fax: (519) 661-3797. Please do not contact the editorial
staff at home. All inquiries hould be directed to the
cla representatives or sent to the Journal's e-mail
addre s: journal@lrc.med.uwo.ca.
Submissions w hich do not follow these guidelines
will not be accepted for publication.
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journals, like fashions, change with the times.

t its debut in 1930, the UWO Medical Journal was
a paperback-sized volume of about 50 pages,
devoted mainly to cientific review articles and,
somewhat later, research abstracts and book reviews. Its
advertising emphasized medical upplies, including golf
clubs, "elixirs", and the "highly palatable" quick-energy
beverage, Vi-Tone. Among the Journal's arly
contributors were some unknowns who later ro e to
celebrity, notably Murray Barr of "Barr-body" fame, who
wrote several article as a student and fledgling
physician, including a charming piece on moulding brain
models out of clay as a way of learning neuroanatomy.
The Journal's original format and spare, elegant
design survived with only minor changes through the
Great Depression and World War II. But by the early
fifties, its clinical austerity was softened by a regular
feature called "In a Lighter Vein", which offered local
medical humour and poetry. Seldom anthologized, much
of this poetry can be found only in the back issues of the
Meds Journal. Starting about 1965, the Journal passed
through a rapid eries of metamorpho e , changing its
look almost yearly until, in the late eighties, it had
slimmed down to 10 or 15 pages, with sports roundups,
ocial calendars and comics pages called "In Stitche " and
"Leisure Seizures".
Then came a major change behind the scenes. Since
its incep tion, the Journal had been published by the
Hippocratic Society, now known as the Hippocratic
Council. But in the early ninetie the Journal became
independent of the Council. Under the new regim , the
page count grew, there was a renewed empha is on
educational articles, and each issue was built around a
special feature topic to provide a focus. At the same time,
we acquired Willow Press as our printer and our
advertising was contracted out to View-an-Ad, thus
guaranteeing the funds to publish two issues a year.
These changes have resulted in a eries of exc llent
publications. But they have also limited involvement in
Journal activities to a handful of tudents. Moreover,
almost all of the articles we have received in recent years
have been scientific or clinical. While this type of article
will continue to be a focu of the Journal, we have now
taken steps to expand our cope by establishing regular
columns on Promotion and Prevention, History of
Medicine, Ethics, and Medical Myths. The first
installment of Promotion and Prevention appears in this
issue, and all four columns should be up and running in
the next edition. We ha e brought on four new taff
member to seek out and edit material for these sections,
but we want to enlarge our contributor base much
further, by inviting article from other faculties or even
from outside the Univer ity, and by inciting more of our
readers to make their mark on these pages.

A
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For the future, we aim to computerize further the
Journal's operations, and to establish a peer-revie w
procedure, which will improve the quality of th e
contributions and will also expose students to the realworld process of publishing a scientific paper. I hope that
all these change , in the works and yet to come, will
increase participation in the Journal and make it a wider
forum for the enlightenment of the medical community
on scientific, ethical and hi torical topics.
Our next is ue will feature ew Technologies in
Medicine. If you are interested in writing or doing
graphics on this topic, or for any of the regular sections,
please contact me or one of the other editors. When your
piece is published, mention it in your CV. I urge you to
follow Dr Murray Barr's footsteps to greatness by
contributing to the UWO Medical Journal.
Ctil{/y JfoJII!.:iils,

'Ed!lor

n

9..11.
(~

J

Physicians
Wanted
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and six pediatricians. We are interested in building
our group and extending our presence in
surrounding satellite communities. We are looking
for board-eligible/board-certified, intemal medicine
physicians who are team oriented and value driven.
Please send your curriculum vitae to:
Lewi Irvin,
Chief Admini lrative Officer,

Geneva Medical Group, L.L.P.,
324 W.

orth Street,
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AN INTERVIEW WITH
MEDICAL GENETICIST
DR JACK JUNG
by Lisa A. Calder BScH, M eds 2000

"Do you like dinosaur ?"
the doctor asks the little
boy. A timid 7-year-old
sitting on his mom's lap
silently nods.
"What kind of dinosaur is
this one?"- Dr Jung points
to a model on his desk.
"A long neck", the child
triumphantly replies.
And so a bond is made.
-Dr fung in the midst of a day of
clinical practice at the Regional
Medical Genetics Centre
(RMGC) of the London Health
Science Centre, Westminster
Campus.
M edical genetics may not be the fi rst specialty that comes
to mind w hen ponderin g th e poss ibilities of a career in
medicine. Dr fung hopes that this is chang ing. Through this
interv iew, one gets a sense of the excitement of being in a
g round-breakin g f ield that s uccessfully combin es man y
cl inically fa sc inating iss ues w ith f undam ental biolog ical
questions. This is a profile of a man who truly loves his work as
a medical geneticist.

D

r Jack Jung is the director of the Regional Medical
Gene tics Cen tre (RMGC), an institution which
works in partnership with many program of the
London Health Sciences Centre. He is also a father to
two beautiful girls, aged 3 and 7, whose picture he
proudly displays in his office. Chat with him for a while,
and you 'll soon discover he is also an avid fan of fl y
fishing .

completing an honours degree in genetics, Dr Jung
embarked on what he terms an "adventure" at the
Uni versity of Calgary in the undergraduate medical
degree program . At the time, the medical school was in
its infancy; beginning a new curriculum that
emphasized self-directed learning to such a degree that
examinations were non-manda tory. Students were
obliged to write a comprehensive exam at the end of
their third year in the program; but the freedom to
pursue one's own learning objectives was much enjoyed
b y Dr Jung. Upon completing his MD, he pursued
specialty training in paediatrics, following which he was
in v ited by Drs Judith Hall and David Smith at the
University of Washington to train in medical genetics.
Equipped with a Canadian Medical Research Council
post-doctoral fellowship, Dr Jung moved to Seattle.
Monoclonal antibodies became the focus of hi s
research in Seattle, as he worked towards iden tifying
s pecific differentiation proteins hypothesized to be
involved in the development of stem cells. The model
used for testing this h ypo thesis was the switching of
foetal haemoglobin to adult haemoglobin. Ba ic science
research impressed him and he mar els at how "it is still
a major challenge to try and understand very basic
biological phenomena".
Following his fellowships, he eventually found his
way to London. He was attracted to London because of
its relati v ely small s ize, allowing for professional
development and the po sibility to effect a significant
impact. Having now been here for 15 years, he confirms
he undoubtedly made the right choice: "It's a sense of
balance that holds me here ... balance of personal life with
professional, balance within professional work between
clinical and academic work and teaching ..."
CLI NICAL R ES EARCH- RELATING CLINICAL
SCENARIOS TO BIOLOGY BASICS

HOW TO BECOME A MEDICAL GENETICIST 101
Dr Jung began his undergraduate career in the early
seven ties at the University of Bri tish Columbia in a
general biology program. His first introd uctory course
to genetics was taught by Dr Tony Griffi ths, former
president of the Gene tics Society of Canada, whose
clarity in the presen tation of persuasive logic was
apparently captivating. Dr Jung was encouraged by Dr
Griffi ths and another prominent geneticist, Dr David
Suzuki, to enter into a program of genetic science. After

Indeed Dr J ung does balance a variety of roles :
clinician, teacher, administrator and researcher. The
major thrust of Dr Jung ' s research has been clinical
d ysmorphology. He contends that while many associate
this area with the study of very rare genetic syndrome ,
" I feel very strongl y that these challenging clinical
scenarios are important links to questions of basic
(science) research ... " He exp lains t hat clinical
d ysmorphology involves the recognition of unu sual
developmental problems as distinct clinical entities, that
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in alliance with basic science can be explored at the
molecular level. Dr Jung comments that, "through the
use of a combination of molecular, biochemical, and
cytogentic techniques, scientists have been able to link
genes to clinical phenotypes identified by clinical
dysmorphologists." Dr Jung also pointed out that this
kind of knowledge is essential to developing potential
therapies for the e genetic conditions.
Other avenues of Dr Jung's research have included
several studies related to neurofibromatosis ( F), an
autosomal dominant disease characterized by
subcutaneous benign tumours and cafe-au-lait spots.
His work with his colleague in thi area has included
characterizing a mutation of the NF-1 gene, de eloping
a polymerase chain reaction (PCR) based approach to
molecular and prenatal diagnosis of
F-1 and
clarifying the relationship between familial segregation
of phenotype and mutation of the F-1 gene.
Further recent work has looked at the cardiac
creening of children with Down's yndrome and, in
another study, the genetic predisposition for the
everity of foetal alcohol syndrome. In addition, the
RMGC is currently involved in a large multicentres
clinical trial dealing with breast cancer, that is funded
by the American ational In titute of Health. One of
the objectives of the trial is to determine the regional

YOUR SUCCESS
IS VVITHIN RE 4 CH
At Bank of Montreal,
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business opportun it ies.
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current banking needs, talk to
Bank of Montreal first.
We can help you w ith financial services
and expert advice on issues such as cash
m anagem ent and financial structuring.
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frequency of the various types of mutations of BRCA1 ,
a recently discovered breast cancer gene. While the
study i anticipated to run for 3-4 years, Dr Jung says
that the RMGC and London Regional Cancer Centre
have already enrolled over 100 families with a very
high incidence of familial cancer. They are currently
undergoing genetic analysis.
SOME OF THE PARAMETERS O F CLIN ICAL
GENETICS PRACTICE
While Dr Jung is very involved in genetics
research, he indicates that his true love remains with
clinical work and teaching. Over the years, many of the
exciting advances in genetics have had far-reaching
implications. Dr Jung's practice of medical genetics has
evolved from being primarily oriented toward
paediatric issue to encompassing a significant adult
population, who present with questions about familial,
hereditary and late onset cancers or neurodegenerative
disea es. He al o notes that prenatal coun elling is
evolving and has to keep pace with the rapid
developments i n very disease-specific molecular
genetic technologies.
Another important component of his practice as a
medical geneticist is genetic counselling: "I don't think
there is any great mystique to genetic counselling- it is
based on good principles of medical practice. When
patient or familie present them elves to a doctor, it's
that process of imparting information so that i t 's
under tandable to the patient and the family tha t is
important."
SHARIN G KN OWLEDG E WITH TH E NEXT
GENERA TIO
One of the key to successful genetic counselling is
good communication. In observing him interact with
his patients and their families, it is clear the Dr Jung is
a gifted communicator. This also comes across in the
genetics cour e he teaches in Phase I of the
undergraduate medical program at the University of
Western Ontario. Dr Jung structures the course such
that fundamental genetic principles are illustrated
through actual di cussion with patients during
lecture .
"My personal teaching philosophy is to how real
life situations that will help the students understand
why the basics need to be understood (for example a
biochemical pathway or the structure of D A). When
students get a chance to be faced with real questions
being posed by the e individuals, it gives importance
and rele ance for the need to understand ba ic a pects
of biology."
In listening to their stories and watching Dr Jung
interact with h is patients, first year students are
learning about the importance of good communication
as well a the ba ic of genetics. The impact Dr Jung
has had on his student is reflected in the teaching
award he has received from the UWO Faculty of
Medicine and Department of Paediatrics.

- - - - - - - - - - - - - - - - - - - - - - - - U.W.O. Medica/Journal 66 (1) 1996
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WHAT DOES T H E FUTURE H O LD?
When asked what he think will be "hot" in
genetics in the near future, Dr Jung suggests that some
of the research focus will shift from monogenic
disorders to polygenic, multifactorial diseases such as
the hyperlipidemias, diabetes and hypertension. In
addition the fundamentals of cell differentiation and
the process of embryological development need to be
further understood. Finally he believes genetic
diagnostics will expand and develop even more rapidly
and that increasing opportunities for gene therapy are
not far off the horizon.
In personal terms, one of Dr Jung's future goals is
to increase his involvement in medical education. His
contagious excitement about his specialty is something
he hopes to be able to pass on to others.
"I've always considered myself extremely fortunate
because within my chosen specialty, you see clinical
problems that frequently pose relevant questions in
terms of basic science - it's a bridge that you can't get
away from in clinical medial genetic practice ... (It's)
more challenging to try and make this connection and I
hope more of the younger generation will pursue
this ... "

1980

• UWO Regional Medical Genetics and
Birth Defects Service is based at CHWO
on South Street. (The service later
becomes known as the Regional Medical
and Molecular Genetics Program of the
London Health Sciences Centre)

1981

• UWO RMGC is accredited for the first
time as a "major centre for service" by the
Canadian College of Medical Geneticists .

1982

• Windsor Genetics Clinic is established as
a direct outreach clinic of the RMGC.

1995

• 420 different physicians in the
Southwestern Ontario Region referred
patients, couples or families to the RMGC.

1996

• RMGC has seen more than 20,000 patients.
The rate of growth in numbers of referred
patients has averaged between 15 and 20%
in each of the 16 years since the centre was
founded.

1

Adapted from: Soltan,H.G. Chronology of Significant
Events in the Development of Human and Medical
Genetics in London, October, 1996.

H ISTORY OF TH E REGIONAL MEDICAL
GENETICS CENTRE (RMG C), LONDON H EA LTH
SCIENCES CENTRE'
1921-1945 • Dr Madge Macklin provides advice to
local physicians on genetic matters. After
publishing over 100 genetic-related
articles, she is recognized as a pioneer in
medical genetics in orth America and is
elected president of the American Society
of Human Genetics in 1959.
1949-1969 • Dr
Murray
Barr
publishes
a
neurohistological study identifying th e
sex chromatin body (Barr body) and
pointing to its clinical significance. Over
next 20 years he brings international
recognition to the University of Western
Ontario as Dr Barr is established as one of
the founders of human cytogenetics.
1965

• One of Ontario 's first cytogenetic s
laboratories is instituted at Victoria
Hospital.

1972

• A Genetic Counselling Clinic is
established in the Department of
Paediatrics at the new University
Hospital.

1974

• The Birth Defects Evaluation Clinic is
founded at the Victoria Hospital to
provide prenatal counselling and genetic
amniocentesis.

Research
means
one thing. ••

(ife.
For thousands of Canadians, Sandoz research has meant a
new lease on life following organ transplantation. Thanks to
research into immuno-suppressant agents, people of all ages are
celebrating successful transplantations. And so are we.
We are celebrating more than ten years since our clinical trials
began on an agent that has changed transplant medecine forever.
And the research continues.
Our research has meant a breakthrough for medicine. For
thousands of Canadians, it means life.

Research means life.

A SANDOZ

SANDOZ: CANADA INC.
Dorval . Quebec H9R 4 P5
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P r omo ti on

a n d

Children

P r e v e n t io n

and the Prevention
Heart Disease

of

by Dennis Klironomos, Meds 2000

stitch in time save nine" is the central thrust of
preventive medicine. It is much easier to employ
preventive measure than to deal with the often
me y consequence of an uncontrollable di ea e process.
Therefore, if a di ease proce can be slowed or controlled
during the early stages of life, severity of illness can be
dra tically reduced later on. The paediatrician's role is
therefore key to the management of many di ea e , not
the least of which is cardiovascular disease, which is
theoretically preventable by changing certain life tyle
patterns. Healthy habit such as exercise and proper diet,
and the avoidance of unhealthy habits such as smoking,
should be lifelong lifestyle patterns which should be
firmly entrenched a early as po ible.
Coronary heart di ease is the leading cau e of death
in orth America, re ponsible for over 500,000 death
annually. ' Surprisingly enough, even though these
numbers are not typically a sociated with the paediatric
population, deaths are rarely due to a sudden
pathological process. Rather, it is the endpoint of a
lifetime of damage, a disease process that begins in
childhood and early adolescence. It has long been known
that fatty streaks, thought to be the pathologic precursors
of atherosclerotic plaque, appear in childhood. Young
American soldiers who died in the Korean war were
shown at autop y to ha e disseminated evidence of
atherosclerosis. ' This implies that aggressive early
intervention is necessary to fight a disease that span
many decade in its course.
Cholesterol screening has been sugge ted, although
not without controver y, a an early measure to identify
candidates for cholesterol-lowering diets. This is
controversial due to the fact that cholesterol levels may be
high in childhood yet normal and without any
pathological consequence later in life. It should
nevertheless probably be implemented becau e a healthy
diet early in childhood can have few if any deleterious
effects, while promoting healthy lifestyle habit for the
future.
Although childhood hypertension is not common,
prevention still must be a concern for tho e who care for
children. Children who are obese have higher blood
pre sure than their lean counterparts. Measures to
address the prevention of hypertension should focus on
appropriate dietary measures, including reduction of fat
and salt. Furthermore, regular aerobic exercise plays an
important role in the prevention of hypertension.2

A

ABOUT THE A UTHOR

Dennis Klironomos is pre ently a first-year medical student at
UWO. Before entering medical school, he completed a
Bachelor of Science degree in Anatomy at McGill University.
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Circulating blood lipid levels, cholesterol, physical
inactivity, smoking and obesity should all be actively
targeted by paediatricians, parents and school
administrators. Healthy dietary patterns in children can
greatly decrease the risk of heart disease, and therefore
nutritional education at home and in school should be a
prime concern. To this end, a student organization known
as "Health Matters", establi hed by UWO med ical
tudents, is planning to engage in a nutritional education
program in local elementary schools. Their aim i not
simply to inform, using the conventional didactic
approach involving the four food groups, but also to
change behaviours and attitudes about nutrition through
the use of small group teaching. A family-oriented
approach including practical nutritional teaching (label
reading and recipe modification) combined with
behavioural contracting techniques, and an exercise
program has proven succes ful in the modification of
cardiovascular ri k factors, including being overweight.<
Habitual cigarette smoking, tobacco use, and aJcohol
consumption are reported in one-third of adolescents and
young adults. These habits have their roots in early
childhood .3 (Tobacco companies realize that their
customer ba e i dying, and that in order to maintain
profits they must recruit a young generation of mok rs.)
Tobacco companies in the United States have used
advertising that appeals to young people. The adorable
cartoon figure of 'Joe Camel' portrays to children and
young adole cents that smoking is 'cool' and adorable.
Even the Marlboro Man appeals to young adolescent
through the use of 'cool' images linked to smoking.
Legislation in Canada i aimed at limiting cigarette
advertising in general, and pecifically at limiting
marketing ploys aimed at children and young
adolescents. Parents, teachers, legislators and
paediatricians hould collaborate to ensure that the
younge t of our population do not succumb to the pitfall
of smoking. In young men who die in accidents, the
increa ed occurrence of athero clerotic lesion in tho e
who smoked tobacco compared with those who had
similar cholesterol levels but did not use tobacco
demon trates the need for early intervention. 2
Paediatricians can also discourage smoking in parents, as
passive smoking can also have deleterious consequences.
Physicians should take an active role in educating
children about the harmful and addictive nature of
smoking.
Phy ical inactivity has become of increasing concern
as our society becomes more electronic and consequently
sedentary. Phy ical activity hould be promoted at
school, not only through physical education, but also
through the encouragement of an active life tyle by
parents and physicians. An a ociation has been found
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between viewing television more than 2 hours per day,
p oor dietary habits, and eleva ted cholesterol levels in
children. Television viewing should be limited to 2 hours
or less per da y, with a policy of no ea ting or drinking
w hile w atching programs. Furthermore, a t leas t 30
minu tes of physical activity 3 days per week, in addition
to that obtai n ed from scho ol ph ys ical education
programs, is essentiaP
Health promotion and disease prevention is probably
as old as the practice of medicine itself. In recent history,
the prevention of infec tious disease through the use of
vaccines, antibiotics and improved antiseptic procedures
has been remarkably effective. Almost every new HIV
infection is entirely preventable, either through the use of
sterile needles, condoms or community-based educational
program about HIV transmission. Thus the importance
of preventive medicine cannot be overemphasized. If one
contrasts the high cost of hospital care after m yocardial
infarction with the small price of nutritional counselling,
it becomes very evident that primary care and prevention
can be the most cost-effective strategy in the promotion of
cardiovascular health}
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lnterventional radiology in
modern hospital setting

a

by Dimitrios Papadouris, Meds '98

INTRODUCTIO N
ntervention al radiology is a relatively new discipline
that offers many services. It has emerged in the last
15 years to provide alternatives to many surgical
procedures. The benefits of interventional procedures
include local anaesthesia and sedation instead of a
general anaesthetic, shorter recovery periods, lower cost
and the ability to treat ill patients who are not surgical
candidate Y Unfortunately, medical education has
lagged behind these advances and the majori ty of
medical students, while exposed to diagno tic
radiology, are unaware of interventional radiology and
the services that it provides . Thus, the focus of this
article i to give medical students and clinician a
simple, comprehensi e overview of the field.

I

P ERIPHE RA L A N GIOGR A PHY A N D VA SCULA R
INTERVENTIO N S
The root of modern interventional radiology are in
cardiova cular procedures. Peripheral angiography,
fir t performed in the 1920s, was neither practical nor in
widespread use until the 1950 , when the Seldinger
method wa introduced . Since then, angiography has
developed from a purely diagnostic procedure to one
that also allows therapeutic inter entions. 3 Angioplasty
has complication rates lower than surgery and patency
rates, in properly selected patients, that are equivalent
to those achieved with surgery. 4
Angiography is used to diagnose primary vascular
di ease such as vasa-occlusive disease; to define the
anatomy in arteriovenous malformation or aneUiy m ;
and to localize small vascular tumours such as
pancreatic insulinomas or parathyroid adenomas.
Moreover angiography is performed prior to any
therapeutic vascular procedure such as balloon
angioplasty,
thrombolysis,
embolization,
chemoembolization, stenting or atherectomy.
Pre Uigical angiography is also performed to establish
the vascular anatomy before tumour resections,
transplant and revascularization procedures. 5
The absolute contraindication to any of the above
procedure is a medically unstable patient. 5 Other
relative contraindications include recent myoca r dial
infarct, coagulopathies and pregnancy. 5
In therapeutic angiography, the tool at the dispo al
of the radiologist are the angioplasty balloon, and more
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recently stents and covered tents. Most experience
with percutaneous transluminal angioplasty (PTA) has
been in the lower extremities and aortoiliac region.
Vascular lesions have been classified into four
categories ranging from category 1 where balloon
angioplasty is the treatment of choice to category 4
where surgery is preferred. This classification is based
on the nature of the le ion (steno is vs. occlusion), its
location, and it length . 6 Endovascular stents make
many category 3 and 4 le ions amenable to
percutaneou therapy. Stents are also used when there
is an unsatisfactory PTA result, as is the case in elastic
recoil or intimal dissection. 6
Angioplasty techniques have recently been applied
to the arteries of the head and neck. Carotid angioplasty
is at pre ent re erved for cases of surgical failure or
high risk patients that are not urgical candidates. 7
Vertebral artery angioplasty is successful in properly
selected patients with lesions at the origin of the
vertebral artery and can be the treatment of choice for
the e lesions.7
Interventional procedure in trauma were
classically restricted to diagno tic angiography.
Following the in titution of le s invasive tests such as
CT, the use of diagnostic angiography in this setting
decreased. At pre ent, therapeutic interventional
procedures have a role in selected trauma patients with
internal haemorrhage. The goal of arterial embolization
therapy is to stop bleeding and tabilize the patient. 8
The use of covered endovascular sten ts for this purpose
has also been described in some centres. The major
limitation in the performance of the e procedure is the
availability of a skilled interventional team, with a
rapid respon e time, 24 hours a day, in an appropriately
equipped level 1 trauma center. 8 A the benefits of
emergency interventional radiology become apparent,
the availability of these services will become more
wide pread .
Other indications for transca t heter artery
embolization, outside the trauma setting, include
bronchial artery hemorrhage, obstetrical hemorrhage,
gastrointestinal bleeding, arteriovenous malformations,
testicular varices, bone tumour , high-flow priapism
and chemoembolization of liver tumours. 5
C ENTRAL VENOUS ACCESS
Modern medicine often requires venou access for
therapy and diagnosi (blood tests) . Therapies that
require central venous acces
(CV A) include
haemodialysis, total parenteral nutri t ion and
chemotherapy for microbial or neoplastic disease. 9 As
the indications for these therapies continue to increase,
the use of CV A will increase.
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Although CV A catheters have traditionally been
inserted by surgeons in the operating room (OR),
pre ent standard practice in most institutions is to place
these catheters radiologically. Advantages of
radiological placement over surgical placement include
a s horter waiting time (usually less than 24 hours),
quicker recovery because general anaesthetics are
avoided, and lower cost to the institution because
radiological suites do not have the o erhead of an OR
and a recovery room.
CVA catheters can be placed in various sites
including the antecubital veins (usually short-term) ,
subclavian veins, internal jugular veins, hepatic veins
and inferior vena cava. The selected route depends on
the ty pe of catheter, anticipated duration of access
requirement and most importantly, the availability of
sui table patent veins. 9
The long-term CV A catheters used at present have
ei ther a subcutaneous tunnel or are attached to a
subcutaneous port. The catheter is placed in two steps.
First, ve nous access is achieved using standard
percutaneous access techniques and a sheath is placed in
the vein. The catheter is then tunnelled subcutaneously
and placed in the vein through the sheath. When placing
a port, a pocket is created subcutaneously for the port
and then the catheter is tunnelled and placed as before.9
With the present use of CV A catheters no longer
confined to an inpatient setting, outpatients continue
with activities of daily living while a CV A catheter is in
place. This type of stress has forced catheter design to be
improved, reducing thrombotic and infectious
complications of long-term CV A. 9

GASTROINTESTINAL INTERVENTIO N S
One of the most common GI interventional
procedures is placement of gastrostomy or
gastrojejunostomy tubes . These procedures are
preferentially performed radiologically as surgical
placement is associated with delay in starting feedings,
increased incidence of aspiration, wound infection and the
possibility of a temporarily delayed gastric emptying
.
5
tim e.

The major indication for placing a gastrostomy or
gastrojejunostomy tube is to provide nutritional support
in patients capable of absorbing nutrients enterically when
mechanical or functional disorders (e.g. head and neck
lesions, neurological disorders) do not allow adequate
feeding by mouth . 5 · ' 0 · ' ' Other indications include
decompression in small bowel obstruction and in
conditions associated with decreased gastric motility. 5·"
Contraindications for this procedure include the
presence of a ventriculoperitoneal shunt (absolute),
bleeding disorders, difficult percutaneous access, massive
ascites, gastric wall lesions and abdominal varices. 5
Other GI procedures include caecostomies in children
with faecal incontinence and dilatation of enteric
s trictures. In malignant dysphagia, dilatation of the
oesophagus may palliate otherwi e inoperable carcinomas
of the oesophagus. Other diseases, including primary lung
cancers and mediastinal masses, can also compromise the
oesophageal lumen. Oesophageal dilatation and covered
stent placement, not in widespread use at present,
improve quality of life in patients with oesophageal
dysphagia and oesophagorespiratory fistula. 12
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BIOPSY

One of the most frequently performed procedures in
interventional radiology is the image-guided needle
biopsy. This technique can be used to sample most
lesions in the chest, abdomen, pelvis, soft tissues and
retroperitoneum. 11 Guidance for biopsy procedures is
provided by ultrasound, computed tomography (CT),
fluoroscopy, or combinations of the above. Success rates
for radiological biopsies are typically very high and
complication rates are low because of the use of small
calibre needles. In a large series by Parker et al.,
adequate tissue for histology was obtained in 97% of
cases and sampling of target tissue was obtained in 92%
of cases when using a biopsy gun. 13
ABSCESS DRAINAG E

The development of percutaneous drainage as a
first-line treatment of abscesses is partially due to
advances in cross sectional imaging. Ultrasound and CT
can document a safe access route to an abscess, allowing
the interventionalist to avoid vital structures while
approaching deep seated collections.
Successful percutaneous drainage can be attained
for abscesses in pelvic, pancreatic, retroperitoneal,
hepatic, subphrenic, thoracic, splenic and
musculoskeletallocations. 11 Although previously viewed
as contraindications to percutaneous treatment, the
presence of multiple abscesses, loculations or enteric
communications do not preclude treatment
radiologically at present. 11 •14 Other types of abscesses
which previously would not have been treated
percutaneously include lymphoceles, empyemas and
amoebic or echinococcal abscesses. 1' When performing
fine needle aspiration of an abscess for diagnostic
procedures, organs and bowel may be crossed but when
placing a drainage catheter a direct access route is
preferred. 5 Other patient conditions which require care
are coagulopathies and access requiring the
transgression of the pleural space. 5
Most abscesses can be cured with percutaneous
therapy. Benign cysts treated percutaneously will often
recur and require sclerosants to ablate their secretory
surfaces. 14 Some complicated abscesses which are
multilocular, purulent, contain necrotic tissue or have
enteric communications may not be curable by
percutaneous means. This situation most often occurs in
patients with pancreatic abscesses, or abscesses caused
by leaks from enteric anastomoses. In these cases
percutaneous therapy is of temporizing benefit, helping
the patient recover from the acute illness and allowing
the surgeon to plan a definitive surgical cure electively. 11
BILIARY AN D GALLBLADDER INTERVENTION S

Endoscopic retrograde cholangio-pancreatography
(ERCP), performed by endoscopists, is the preferred
method for visualizing the biliary ductal system and
placing stents for biliary ductal obstruction. When this
procedure is unsuccessful or not possible, percutaneous
transhepatic cholangiography (PTC) is performed.
14

Although more invasive, PTC offers superior resolution
of anatomic abnormalities in the biliary system when
compared to other radiological methods (e.g. CT, US or
nuclear medicine). 11
The actual procedure involves placing a needle into
an intrahepatic bile duct and then injecting contrast to
delineate the ducts. This procedure is easier in a patient
with a dilated biliary system but can be accomplished in
85-90% of patients with non-dilated ducts. 11 As biliary
infection is prevalent in patients with biliary
obstruction, it is important to provide adequate
antibiotic coverage with broad spectrum prophylactic
antibiotics. 5
If a PTC shows a biliary obstruction, one can
proceed to drain the biliary system percutaneously.
Percutaneous drainage is designed to relieve biliary
obstruction and associated jaundice, pruritis, biliary
sepsis or cholangitis. 11 To achieve drainage, a catheter
can be placed in the biliary system through to the
duodenum past the obstruction. These catheters have
side holes that are positioned above and below the
obstruction. Endoprostheses, which achieve drainage in
the same manner but are completely internal, can be
placed radiologically or endoscopically. The drawback
to endoscopic stenting is that often the endoscopist
cannot traverse the stricture. In these cases a rendezvous
procedure is done where the radiologist places a
guidewire percutaneously across the stricture into the
duodenum and the endoscopist then inserts the internal
stent over this wire.
Biliary stone removal can also be done
percutaneously. Both common duct stones and
intrahepatic duct stones can be removed using basket
extraction, injected dissolvants and cholangioscopic
lithotripsy through a percutaneous tract. 15 Transhepatic
basket extraction and lithotripsy procedures are done in
two stages with a tract being created by using aT tube,
allowing this tract to mature for 5-6 weeks and then
actually removing the stone. 15
In the gallbladder, percutaneous cholecystostomies
are performed. Indications for cholecystostomy include:
drainage of purulent material in a patient who is a poor
surgical risk; unexplained sepsis with an abnormal
gallbladder on US; to stabilize a patient prior to
cholecystectomy; or to remove gallstones. 5 Less
commonly, biliary drainage can be achieved in a patient
who has a blockage downstream from the cystic duct. 11
GENITOURIN ARY IN TERVEN TIONS

Just as percutaneous transhepatic cholangiography
is the initial step in biliary interventions, percutaneous
nephrostomy (P ) is the initial step in genitourinary
intervention. The PN can be used to drain the renal
collecting system in the setting of pyeloureteral
obstruction or sepsis. It is also used to gain access to the
collecting system for the placement of ureteral stents or
to divert urine from the ureters, allowing healing
following ureteral injury or fistula. 5•11
In the treatment of renal stones, extracorporeal
shock wave lithotripsy is the method of choice. In cases
of large stones or when complications from
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extracorporeal therapy occur (ureteral obstruction),
percutaneous intervention is indicated . A P can be
u ed to debulk large tones prior to lithotripsy and can
also provide a passage for fragm ents pos t lithotripsy."
Other a pects of renal intervention include biopsy of
le ion , treatment of cysts or ab ce e and treatment of
pos t renal transplant complications . All of the e
indications involve percutaneous methods mentioned
previousl y.
CAVAL AND PORTAL VEN O US INTERVENTION S
Two procedures which ha v e gained popularity
recently are percutaneous placement of inferior vena
cav a (IVC) filters and tran s jugular intrahepati c
portosy temic shunts (TIPS).
Indications for IVC filters include the patient who is
refractory to, or has compl ica tions associated w ith ,
a nticoagulant therapy and po e a significant risk of
d eveloping a pulmonary embolus. The placement of
these filters percu ta n eou s ly is a st r aigh tforward
procedure that can be life saving. A recen t advancement
is the u e of temporary or retrievable filters which w ill
be of benefit to patients with reversible conditions.'
Transjugular intrahepatic porto ystemic shunts are
indicated for portal hypertensive haemorrhagi c
complication , intractable a cite and in Budd-Chiari
syndrome. The procedure in volves entering the cava l
system via the right internal jugular vein and advancing
a guidewire into a main hepatic vein wi th a small calibre
ca theter. Then , using a ne e dle advanced over th e
g uidewire, the portal
y tern is punctured
intrahepatically. The final tage i balloon dilatation of
the connecting tract and placement of a stent. A major
problem with TIPS is a stenosis rate of 25% at 6 months
and about 50% at a year. Thi necessitate routine follow
up of the tent with Doppl er US and revision of the
procedure if stenosi is found .5· 16
The role of TIPS has yet to be defined. At present it
is preferentially used in high-ri k patien t with variceal
h e morrhage who are not res ponding to endoscopi c
clerotherapy. l6 In the future, if long-term patency rates
a re improved by the use of newer methods, TIPS ma y
ha ve an increased role in treating lower risk patients
that require portal system decompression .16
CONCLUSION
In the management of the ill patient that may benefit
from an interventional procedure, it is important to use
th e interventionalist as a co n s ultant, much like a
surgeon . This will allow the determination of the bes t
treatment modality for the patient be it medical, surgical
or interventional.
ACK OWLEDGEMENT
The author would like to thank Dr Ray McLoughlin,
an interventional radiologist at University Hospital, for
his help in preparing this manuscript.

c

e s

REFERE CES

1. Baum S. The radiologist inten>enes. Eng/ f Med 1980; 302:1141-2.
2. Struck OW, Bennett JO, Koznk Rl. Insertion of subcutaneous cmtral
t•enous infusion ports by inten•entional radiologists. Can Assoc Radio/ I
1995;46:32-6.
3. Geddes LA, Geddes LE. The catheter introducers. Mobium Press, Chicago,
IL. 1993.
4. Casta0eda-z·6iga WR, Tadavarthy SM. l nterventional Radiology, 2nd
ed. Williams & Wilkins, Baltimore. 1992.
5. Kandarpa K, Aruny JE. Handbook of lnterventional Radiological
Procedures, 2nd ed. Little, Brown and Compmry, Boston. 1996.
6. Becker Gj. Stmt placement for peripheral arterial disease of the lower
extremities. JVIR 1996 Supp/.;7(1):181-90.
7. Sclrwarten DE. Extracranial mrgioplasty. JVIR 1996 Supp/.;7(1):265-70.
8. Selby JB. lnten>entional radiology of trauma. JVIR 1996 Supp/.;7(1):32734.
9. Mauro MA, Jaques PF. Radiological placement of long-term central
r>enous catheters: a review. JVIR 1993; 4:127-37.
10. emcek AA. Gastrointestinal interventions: wrrent concepts and future
directions. JVIR 1996 supp/.;7(1):230-32.
11. Mueller PR, vmrSomrmberg E. lnterventional radiology in the chest and
abdomen.
Eng/ f Med 1990; 322:1364-74.
12 .Keller FS. Esoplrngeal Stents. JVIR 1996 Supp/.;7(1):229-30.
13. Parker SH, Hopper KO, Yakes WF, et a/. Image-directed percutaneous
biopsies with a biopsy gun. Radiology 1989;171:663-69.
14. r>anSomrmberg E, O 'Agostino HB, Casola G, eta/. Percutaneous abscess
drainage: Current COncepts. Radiology 1991;181:617-26.
15. Uflacker R. lntervwtions in benign biliary disease . JV I R 1996
Supp/.;7(1 ):225-228.
16. Darcy MD. TIPS clinical update. JVIR 1996 Supp/.;7(1):159-62.

Q

CIBC
PERSONAL
LINE OF
CREDIT

CIBC offers a special financing
program for eligible medical students
who require financial assistance
during their school years.
For details visit
C.!. B.C.
228 Oxford Street East
London, Ontario 6A 117
or Call Evelyn Dodds
(519) 661-8110

erne

U. W .O. Medical Journal 66 (1 ) 1996- - - - - - - - - - - - - - - - - - - - - - - -

15

Articl e s

The Ye II o w
para dig m

•

1

Br
n

i~

k

Road: A new
medical education
by

s we walked into Auditorium A of Univer ity
Hospital on that warm September evening, we
were not dissimilar to the archetypal Tin
Woodsman, Cowardly Lion, and Scarecrow from the
Wizard of Oz. Overwhelmed by looming histology slides,
anatomy di sections, and pile of textbook , we lacked
wisdom, heart, and courage, or at least we thought w did.
Although we were promised a theatrical forum on ethics,
we were unsure what to expect. What we got was a
whirlwind tour through what it really means to be a
doctor. In our constantly changing ociety, a physician can
not be cold and scientificaUy-rninded, treating his patients
like problems out of a textbook. Phy icians mu t be caring
individuals with heightened sensitivity for their patients'
needs, fears, and expectations of them. They must be able
to render medical decisions in such a way as to not only
accommodate patients' medical needs, but to involve them
as partner in the pursuit of their own health.
We were introduced to these is ues by watching a
video of a theatrical, musical performance entitled, "The
Waiting Room. " The entire production, from musical score
to lyrics, was developed by Western medical students
under the direction of Dr. Jeff isker, the architect of the
YeUow Brick Road program. Through song and music, we
glanced into the lives of three women waiting to see a
doctor. Each woman, while representing a different
cultural and temporal framework, was faced b y the
dilemma of physical self-sacrifice in order to fulfill societal
expectation. The characters featured were a modern-day
American woman whose desire for physical attractiveness
prompted breast augmentation and cancer fear, a Chinese
woman forced by family and cultural tradition to bind her
feet tightly o she could attract a potential mate, and a
woman from Victorian England, who wore society's corset
and was considering oophorectomy to remove mood
changes and sexual thoughts. What we witnessed was a
portrait of how health-related decisions can be made in the
absence of personal choice.
After the video, Dr . isker shared hi vision of
creating a dynamic, multimedia forum for the discu sian
of bioethical and culturally sensitive issue relat d to
medicine. The goal is to form a program that employs
pre entations such a plays, literature, theatre and
narrative seminars to address complex issues that we, as
students and future practitioners, will face. In the ensuing
discussion, the class showed a great awareness for the
importance of ethical decisions and how they shape
medicine. The term informed consent was left a ide for the
more appropriate phra e informed choice, a physicians
should by no means seek to impose their will on patients,
and simply seek a signature on a consent form.
Other issues that surfaced for exploration included
female genital mutilation, a common practice in many
African countries affecting millions of women. This is an
example of how cultures can influence per anal health
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choice ; women from the e traditions often feel it their
duty to undergo uch procedures in the name of culturally
ascribed practice . Understanding the ri ks and benefit of
a procedure is very important, as cultural factors, gender
control issues and the undue influence of role models may
skew patients into making personal decisions that they do
not want to make. After discussion, we arrived at key
factors which we felt were essential for an informed choice.
Patients must be educated about their own health
concerns, display confidence to make their own choices, be
independent or free from coercion, and be competent and
autonomous. With these attributes, patients become
empowered to make decisions that directly affect their own
health. It wa acknowledged by the group that it is the
phy ician's role to provide this empowering atmosphere
for the patient.
Linked to the empowerment of the patient is the
autonomy of the physician, who, as an individual, has the
ability to refuse to perform a treatment such as genital
mutilation based on a personal ethical choice. In times of
conflict, how do physicians express their right to autonomy
without appearing culturally insensitive or discriminative?
From the physician's standpoint, an attitude of placing the
decision firmly in the hands of the patient should be the
ideal. But, patient autonomy ometimes conflicts with
social benefit and in these instances it is probably better to
maintain societal values. For example, a patient requesting
that her gynaecologist perform a form of female genital
mutilation should be refused, even though she may then
proceed to have it done under substandard and potentially
dangerous conditions.
Overall, the bioethics seminar was well received .
Students generally felt that there was a need to bring
bioethical health issues into discussion o that they could
begin to think about the complexities of their profession. It
is important to state that many of the males present felt
intimidated by the Waiting Room presentation .
Specifically, they felt that men were portrayed to be the
sole root of the medical problems that the women faced.
Since historically men have controlled society ' s
imperatives, this juxtapo ition is not unreasonable.
The high level of awareness, cultural sensitivity, and
analytic ability portrayed by the students outlined the
lynch-pin of this new method of teaching: as medical
students passing through a rigorous admissions process,
we already possess the skills, scientific and humanitarian,
to become good doctors. Just like the Tin Woodsman, Lion,
and Scarecrow characters on their journey to Oz, it is
simply a matter of discovering attributes within ourselves.
The purpose of the Yellow Brick Road program is to
maintain and foster our enthusiasm for human i ty ,
compassion, and giving of ourselves to others. These are
virtues often lo t over a lifetime of board exams and hectic
call schedules. Our development of clinical skills need not
interfere with our development as human beings.
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In this way, the Yellow Brick Road represents the next
tep in advancing medical educa tion . Following the
innovation of problem-ba ed learning, the interacti e,
multimedia Yellow Brick Road presentations allow for the
provocative exchange of ideas regarding the socio-ethical
aspects of medicine. The active participation of students in
program design and implementation are instrumental in
ensuring that each issue becomes incorporated into our
"databa e" of sensitivity and compassion. The philosophy
i simple, education through empowerment with bioethical
tools leads to a life-long awareness of sensitive issues, and
this leads to better doctors. In the context of this program,
Western seeks to create a generation of ethically
responsible physicians.
As medical chools aero Ontario continually revise
and redevelop their curricula to embrace the ideals of
EFPO and produce graduates who are better prepared to
provide medical service to their communities, the need for
a program like the Yellow Brick Road becomes apparent.
In the newly rediscovered era of patient-centred medicine,
this program attempts to form the student-centred
curriculum. With sessions already starting to wind their
way to medical chools across orth America, brick by
brick, the Yellow Brick Road i charting new territory and
will certainly be coming to a medical school near you in the
foreseeable future. Here at We tern, we look forward to the
upcoming Yellow Brick Road es ions, which will touch on
a va riety of ethical issues that we, as members of the
medical community, will surely encounter in the future .
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FAMILY PHYSICIANS URGENTLY NEEDED
ORANGEVILLE, ONTARIO
HEADWATERS HEALTH CARE CENTRE, Drangnille is
urgently seeking family physicians for the Orangeville area.
Applicants should have an OHIP billing number and be licensed to
practice in Ontario.

Headwaters Health Care Centre is a new, fully accredited, 1DBbed, acute-care, well-equipped facility which offers a wide range
of quality care including Emergency Department, Obstetrics and Critical Care available 24 hours a day. It is served by 37 Family
Physicians, 30 specialists from 15 disciplines, 5 dental surgeons and supported by more than 400 staff. The hospital will serve a
catchment area of approximately 90,000 full-time and 10,000 part-time residents.
Orangeville is a vastly growing rural area situated one half hour north of Brampton. It offers a very attractive quality of We,
including a new Opera House as well as recreational and educational facilities. It is located less than one hour from major health
science centres and it is convenient to Toronto, Hamilton and Guelph. Enjoy the advantages of rural living with large city
accessibility.
This is a nwanling opportunity Ia deliver exc.Unllarnily practice in a relaxed nand selling.
Interested applicants should make inquiries or send complete curriculum vitae to Mrs. Nancy Ross, Executive Director, or
Dr. F. Lindsey, Chair, Department of Family Practice/Emergency Medicine
Dufferin-Caledon Health Care Corporation, 32 First Street, Orangeville, Ontario, L9W 2E1 .
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Basics: A Short Review
Paediatric Radiology

Se cti o n

of

by Nicole S. Isaac, Meds '97
Douglas J. Moote, MD, FRCPC
he problems diagnosed in paediatric radiology
are different from those seen in adult radiology,
but the method of reading the paediatric film is
very similar. An organized approach is the most
important part of reading films. One approach is
presented in this article, as well as common problems
seen on chest, abdominal and bone films.

T

T H E PAEDIAT RIC CHEST FILM
One approach to the chest film is the ABC's. Before
looking at the image, however, look in the corner at the
patient information. Always make sure that you have
the correct patient name and the correct date of
examination. Look at the age of the patient, as certain
diseases are more common in different age groups .
Then go on to the ABC's: abdomen, bones (and soft
tissues) and chest (lungs, airway, mediastinum,
diaphragm).
ABDOMEN
Examine visible abdomen as if you were reading an
abdominal film (see below).
BONES AND SO FT TISSUES

the time that it takes to radiograph the patient. The
trachea lies to the right of the midline. Deviation from
this position is an important clue to mediastinal
masses as well as differences in hemithoracic pressure.
ote the position of the major bronchi.
2. Mediastinum: This is a difficult part of the
paediatric chest x-ray, primarily because the thymus
obliterates many structures from view. Additionally,
because of the fast respiratory rate and inability of the
infant to cooperate, it is difficult to get an inspiratory
film. Look for position, size and contour of the
mediastinal structures. The thymus has a wavy
contour and may extend from the thoracic inlet to the
diaphragms. It can obscure the lung fields. It should
not alter the position of any structures in the chest.
3. Heart: The heart is situated mainly in the left
hemithorax. It is difficult to evaluate the heart size on
the frontal film because it is not necessarily taken
during inspiration. On the lateral film, draw a line
from the carina straight down to the diaphragm. This
line will intersect an enlarged heart. An enlarged heart
will push adjacent structures such as the carina
posteriorly . It may indicate congenital heart disease.
Tetralogy of Fallot (overriding aorta, right ventricular
hypertrophy, right ventricular outflow tract
obstruction & ventricular septal defect) causes a boot
shaped heart.

It is easy to overlook these, e pecially if there is a
glaring abnormality in the lungs. Make sure that all
normal bony anatomy, (i.e. clavicles, ribs, vertebrae)
are present. Look for abnormal structure, fractures, and
destruction of bone. The spinous processes of the
vertebrae are not fused in children under three. Next,
look for swelling, foreign bodies, and calcifications in
the oft tissues of the neck, thorax, limbs and abdomen.
Beware of artifacts such as clothing, jewelry and skin
folds.

CHEST
1. Airway: This should be visible in all chest films,
from below the nasopharynx to the carina (the division
of the trachea into the right and left bronchi). Evaluate
for patency, position and size. The trachea normally
buckles during expiration in infants. Look for
consistent narrowing of the airway, as this may be a
clue to extra tracheal masses and vascular rings, as well
as tracheal abnormalities. A steeple appearance of the
subglottic airway on inspiration, in addition to stridor
and a barking cough, is pathognomonic for croup. A
thumb-like opacity on lateral views of the upper
airways is seen in epiglottitis. However, this diagnosis
should be made clinically; the airway may occlude in

Figure 1: A 7-year-old boy witII a cli11ical history of p11eumorria. Note tile atr space
disease i11 tl1e rigllt lower lobe witll a11 air fluid level. Tllis hmg abscess resolt'<'CI witll
treatment.
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Figure 2: Tl1e child i11 this film i11ha/ed a pen11ut wl1ich lodged in the left mninstem bronc/ms. Subtle abllon11alities exist 011 all inspiratory film, but with expiratio11, tl~e contrast beht>eell
the 11ormnl collapsi11g rigllt hmg a11d the left lung wl1ich is trappi11g air due obstn1dio11 by the pea1111t is more 11oticeable.

4. Great Yes els: The aortic arch and descending
aorta hould be on the left of the midline. Also look for
the left and right pulmonary arteries situated in the
lung hila.
5. Esophagus: This is po terior to the trachea.
Esophageal air may be normal in the neonate, but is
abnormal in older infant and children.
6. Lymph odes: In pathologic conditions such as
lymphoma, lymph nodes may be visible in the hilar
regions of the chest.
7. Lungs: The lungs are the largest and most
exciting structure seen on the chest x-ray. There are
two fi ures in the right lung and one in the left lung.
Look for any invasive tubes or monitoring equipment
that may hint at the diagnosis or ymptoms, and ensure
that the lines are correctly placed. The left hilum is
s lightly higher than the right hilum , and the right
hemidiaphragm is slightly higher than the left . A
change in this anatomy is frequentl y pathologic. The
heart borders should be harply defined by the air in
the lung . Fuzzy or obscured borders indicate lung
abnormalitie uch as pneumonia, abscess (fig 1), or
atelecta is. Atelectasis results in a decrease in volume
of the affected lung, and adjacent fissures will be
pulled toward the affected area . Consolidation will not
change the lung volume. The location of consolida ted
lung can be pinpointed by the di appearance of normal
anatomy (i.e., the diaphragms are obscured by lower
lobe pathology, the left heart border is obscured by
lingular pathology, the right lower heart border by
right middle lobe pathology and the upper h e art
borders by upper lobe pathology). The costophrenic
angle
hould be sharp. Rounded angles indicate
pleural fluid or thickening . Lung markings (white
lines created by bronchi and va culature) should be
most vi ible in the proximal 2 / 3 of the lung. If a
pneumothorax is pre ent, there will be no vascular
markings surrounding the collap ed lung and the
perimeter of the lung can be visualized. This is be t
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Figure 3: Ultrasound of appendicitis. Ultrasound is used whm tl1e cli11ica/ history is
equit>aca/ in suspected appmdicitis. This appendix l10s thickened walls and a r•i>ible
calcification. Tl1e stone is echogenic (white)(/ong arrow) a11d casts a l1ypoec/10ic (black)
shadow (small arrows) behi11d it.
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seen on expiratory films because decreased aeration
makes the lung denser (whiter) compared to black
pleural air. Expiratory films are also useful to look for
air trapping in foreign body aspiration (fig 2). Other,
more subtle lung field abnormalities include
respiratory distress syndrome (RDS) and neonatal
pneumonia, which often mimics RDS. The lung fields
are small, hazy, with a reticular (net-like) pattern
caused by interstitial fluid and atelectasis, and there
are dilated bronchi. The pattern with neonatal
pneumonia is slightly coarser, with better lung
expansion and pleural effusions.
THE PAEDIATRIC ABDOMINAL FILM
An orderly approach, similar to that used for the
chest film, should be used for the abdominal film.
There should be two views of the paediatric abdomen:
supine and erect (or decubitus), as well as a frontal
chest x-ray.
CHEST
Figure 4:
A newbom child with failure to pass meconium and obstruction on abdominal
radiographs (not included). Note the narrowed rectum (arrowheads) which represeuts the
aganglionic segment in this patien t with Hirsclzsprung's disease. The dilated bowel (curoed
arrows) is histologically normal

Carefully review any visible chest.
BO NES AND SOFT TISSUES
Look at the ribs and pelvis for fractures and
dysmorphism. Ensure that the spinal column has a
normal contour, particularly in the older child who
may have scoliosis . Watch for areas of decreased
density in the bone which might signal malignancy, but
do not be fooled by overlying bowel gas. Look for the
properitoneal fat line (flank stripe) on the supine film.
It indicates the edge of the peritoneal cavity and will
disappear if edematous (peritoneal inflammation). If
the colon is gas filled, it should abut the flank stripe.
Space between the two may be due to peritoneal fluid
or a solid mass.
ABDOMEN

U/trasouud of a 4-week-old boy with a 2-week history of projectile vomiting.
Figure 5:
The pylorus is elongated, with thickened muscular walls (arrows) and a stenotic canal
(curoed arrow). The pylorus starts to curoe with iucreasing size.

Free peritoneal air is always abnormal. It can be
seen below the diaphragm and above the liver and
stomach bubble on an erect film. If there are only small
amounts of air, it may be easier to see it on a left lateral
decubitus film as a thin line above the liver. A 'football
sign" ma y be seen; the lace of the football is the
falciform ligament (normally invisible) highlighted by
a football-shaped lucency of free air. The kidneys are
10-12 em long and located at the Tl2-L2 level, the right
being slightly lower than the left. Their outlines can be
seen faintly on either side of the iliopsoas shadows. It
is important to look for stones and other calcifications
in the kidneys and along the path of the ureters as well
as in other areas of the abdomen. Decide where the
calcification is and determine its character. Ill-defined
margins, irregular outline, and punctate calcifications
are ominous signs, possibly indicative of malignant
neoplasm. An appendicolith may appear in the right
lower quadrant as a cause for appendicitis. In clinically
obscure cases, appendicitis ma y be diagnosed b y
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Figure 6: Tltis clrild rmderwenl a slcelrtal survey for suspected cltild abuse, wlticlr consists of frontal and lateral skull, frontal and lateral spine, fron tal cites/, and upper and lower
extremity radiographs. Along witlt multiple rib and radial and ulnar fractures, tire clti/d tl!tlS fo und to ltave bilateral bucket lumdle and comer fractures (s /raiglrl amnDS), and periosteal
reaction (curved arrows) of bollr tibiae and femora as well as a posteriorly displaced tibia wit It respect to its epiphysis (open a"ow).

ultrasound. A thickened appendiceal wall +I - an
appendicolith will be seen (fig 3). Examining the bowel
gas pattern is a n important part of abdom i nal
radiographic eval uation. Look at the position, contour
and size of the gas pattern. The large bowel frames the
peritoneal cavity, with the small bowel situated centrally.
In infants, this may be the only clue to distinguishing
small from large bowel. The caecum, which has a larger
diameter than the rest of the bowel, should be in the
right lower quadrant. Displacement may be due to
malrotation of the gut. Make sure that the gastric bubble
is under the left hemid.iaphragm for similar reasons. The
bowel walls, highlighted by air within the lumen, should
be smooth and regular. Irregularity may denote
inflammation from diseases such as Crohn's disease,
which has a cobblestone appearance. Physiologically,
there should be less than three air fluid levels. There are
occasionally more in infants and young children. These
show up as menisci between the black (hypodense) air
and the white (opaque, den e) fluid . Multiple air fluid
levels may denote mechanical obstruction such as
volvulus or Hirschsprung 's disease (colonic
aganglionosis) (fig 4). The double bubble sign (2 air-filled
adjacent areas of bowel) is seen with proximal
obstruction such as duodenal atresia. If a mechanical
obstruction has been present for some time, bowel d istal
to the obstruction will be devoid of air. A paralytic ileus
is identified by dilated loops of bowel. A single loop of
dilated bowel is called a "sentinel loop" and is associated
with disease of a specific organ in a localized area, such
as in pancreatitis. Pyloric stenosis is not diagnosed on
plain film, however, the stenotic pylorus is visible with
ultrasound (fig 5).
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THE PAEDIATRIC SKELETAL FILM

As with other types of films, approach the bone
film methodically. Always get at least two views; the
cortex is circumferen tial, while the plain film presents
only a 2-dimensional view.
Look at the soft tissues, joint space and bone. Long
bones, such as the femur, have four parts. The
diaphysis is the shaft. The metaphysis, at the ends of
the diaphysis, is attached to the epiphyseal pla te. The
epiphysis ar ticulates in the joint. Bone age can be
approximated by comparing hand and wrist x-rays to
those in an atlas. Different epiphyses ossify (become
roentgenographically visible) at different ages.
Observe the alignment of the bones. Malalignment
of the bones with respect to each o ther may indicate
dislocation. Bone densi ty is difficult to estimate on
plain film due to differences in film exposure, but
asymmetry or inconsistency within a bone may
indicate a lytic process. Look at the continuity of the
bony cortex and the trabecular pattern. Children's
bones are more flexible than adult's, and a slight
cortical or trabecular discontinuity may be the only
sign of fracture. The greenstick fracture is manifested by
a bowing of a long bone with a discon tinuity of the
cortex (the fracture) on the convexity. Buckling of the
cortex is seen in a torus fracture . The periosteum (the
metabolically active covering of long bones) is not
normally seen except in 2-6 month old infants. A
visible perios teum indicates periosteal reaction to
trauma . It is loosely applied to the paediatric diaphysis
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and with trauma, it can be lifted off the bone. It will
then form a thick layer of new bone within 7-14 days.
This reaction can be u s ed to date a fracture . The
periosteum is more tightly applied to the metaphysis.
A twisting injury can cause corner and bucket han dle
f ractures - a thin wedge of bone is torn from the rim of
the metaphysis and resembles a corner of bone torn off
or the handle of a bucket (Fig 6) . Multiple fractures at
different stages of healing, rib, corner and bucket
handle fractures are virtually pathognomonic for child
abuse. Fractures that involve the physis are classified
under the Salter-Harris classification .
All fractures should be described with respect to
type (open or closed), site, pa tt ern (transverse v s.
spiral, compression vs. greenstick; fragmentation) , and
displacemen t (apposition, angulation, rotation a nd
length) . Some fractures such as supracondylar (elbow)
fractures are difficult to see on plain film. A clue to
their existence is elev ation of the articular fat p a ds the sail sign. The lucent fat pad resembles a sail on the
distal humeral metaphysis.
Dev elopmental dysplasia of the hip is a common
problem best seen with sonography because the hip joint
is not fully ossified in infants. The acetabulum appears
flat instead of being cupped to fit the femoral head.
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The most important thing to remember about
reading paediatric radiographs is to do so
methodically. Knowledge of the pathology and clinical
progression of a disease will help in the identification
of pertinent radiologic signs.
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Novel antipsychotic power for routine use

ZVPREXA• (olanzapine tablets)
THERAPEUTIC CLA S SIFICATION -

Antipsycholic Agent

P HA R MACOLOGY
Pharmacodynamic Properties: ZVPREXA" (oianzapine). a thH!OObenzodiazepine, IS an anb·
psychotic agent, dosplaying high receptor affinity binding In vitro at serotonin 5-HT.,..,
(Ki = 4 and 11 nM, respectively) , dopamine D, , D 2 , D,. D, (Ki = 11·31 nM), muscarinic M, ..
(Ki = 1.9-2.5 nM). adrenergic tt,(Ki = 19 nM), and histamine H, (Ki = 7 nM) receptors. In a behav·
10011 paradigm predicbve of antipsycholic actMty, oianzapine reduced conditioned avoidance
response on rats at doses lower than 4 times those requored lo produce catalepsy. In a single dose
( 10 mg) PET study in healthy subjects, oianzapone produced higher 5-HT20 than dopamone D2
receptor occupancy The percent of D2 occtJpancy was less than the threshold value predictive of
extrapyramodal events.
PhannacoklneUc Properties: ZVPREXA IS well absorbed alter oral adrmniStration. reachong peak
plasma concentrations within 5 to 8 hours. The absorption is not affected by food. Plasma con·
centrations of orally administered oianzapine were linear and dose proportional in trials studying
doses from 1 to 15 mg. The maxmum plasma concentrations (Cmax) of oianzapine after songle
oral doses ol5, 10 and 15 mg averaged 7 , 14, and 21 nglml. respecllvely (20 nglmL = 0 . 064~tM).
In young healthy volunteers, after once-a-day repealed dosing, steady-state Cmax was appro.,.
mately twoce that achoeved after a single dose (eg. 23 ng/mL versus 12 ng/mL for a tQ.mg dose)
In the elderly, the steady state plasma concentration was approximately 3-fold higher than that
achoeved after a single dose (e.g. 16 ng/mL versus 5 ng/mL for a 5-mg dose). In both, young and
elderly, steady-stale concentrations of oianzapone were obtaoned after seven days of once
daily dosing.
Over ume and dosage range, pharmacol<ineloc parameters withon an ondividual are very consostent However. plasma concentrations, half-life and clearance of oianzapine may vary between
individuals on the basis of smol<ing status, gender, and age (see Special Populations). Data from
pooled, single dose pharmacokinetic studies showed the half-lne of oianzapine to range from
21 to 54 hours (5th to 95th percentile). and the apparent plasma clearance lo range from 12 to
47 Uhr (5th to 95th percentile).
The plasma proteon binding of oianzapine was about 93'l. over the concentration range of about
7 lo about 1000 ng/mL Olanzapine is bound predominantly to albumin and a, ·acid glycoproteon. Olanz.apone os metabolized in the live< by COOfU98bve and oxodai!Ve pathways. A mass
balance study showed thai approximately 57% of radiolabeled oianzapine appeared in unne,
pnncopally as metaboiHes. The major circulating metaboiHe is the 1Q-Nijlucuronide. which is phar·
macologocally onaciJve and does not pass the blood brain barrier. Cytochromes P4so-GYP1A2 and
P4so-GYP206 contribute to the formation of the N-desrnelhyl and 2-hydroxymelhyl metaboiHes,
respectJvely. These metabo!Hes do not produce behavioural activrty in the rat at doses 4 to
16 bmes greater than active doses of oianzapone.
In vitro mocrosomal studies show thai oianzapone IS a weak inhibotor of CYPt A2 (Ki = 36 ~tM) .
CYP206 (Ki = 89 ~tM), and CYP3A4 (Ki = 490 ~tM) . Based upon these Ki values, rottte onhibobon
of these cytochrome P-450 enzymes is expected "' vwo at concentrations below 5 11M (roughly
1500 nglmL) because the oianzapine concentration will be less than 10% of its Ki value.
In clinical studies, observed steady-state plasma concentrations of oianzapine are rarely
> t 50 ng/mL (approximately 0.5 11M). Olanzapine IS thus not likely to cause clinically important
pharmacokinetic drug-drug interactions mediated through the metabolic routes outlined above
(see PRECAUTIONS, Drug Interactions).
Special PopulaUons: In a single dose study onvolvong 24 healthy subjects the mean elimonabon
= . et!'tow~ was prolonged in elderly subfects compared with non-<>lderly subjects. as

Men
Women

<65 years
(N=B)

2:65 years
(N:16)

29 hours
39 hours

49 hours
55 hours

Large scale population pharmacokinetic analyses show that the plasma clearance of oianzapone
IS lower on elderly versus young subjects, on females versus males, and in non-smokers
versus smokers. However, the overal variabiiHy between individuals is larger than the magnitude o1
mpact of the ondivodual factors of age, gender or smokong. on oianzapine clearance and half .life
The pharmacokoneuc characteristics of oianzapone (5 mg single dose) were not sOOslantJalty
different in patients with severe renal impaorment and on nonnal subjects. Muftipte-dose
studies in pauents wrth renal failure, however, have not been performed.
No differences on the single-dose pharmacokinetics of oianzapine were noted in subjects woth
cfonocaUy signifocant cirrhosis (who were mcost1y smokers) when compared to healthy subjects (all
non-smokers). Multiple-dose studies in patients woth hepatiC ompairment, however, have not been
performed.
No specofoc pharmacokinetic study was conducted to onvestigate ethnicity effects, but a revoew
of the climcal pharmacology studies identifoed no omportant differences on the disposition of olanzapone on Gaucasoan subjects versus subjects of Afncan descent.
C LINICAL TRIALS
The efficaocy of ZVPAEXA" (olanzapine) in the redUCtion of and maintenance of the reduction of the
manofestations of schozophrenia and related psychobc disorders was established in 3, well-rontrolled clinicallrials of psychotic inpatients who, al entry mel the DSM·III·R cmeria for schizophrenoa (most with a course at entry ol "chronic with arute exacerbation") and 1 welk:ontrolled c1onoca1
tna1 of psychotoc inpatients and outpatients who, at entry, mel the DSM-III·R cmeria lor sctuz<>phrenoa. schozophrennorm disorder, or schozoalteci!Ve diso<der. The results of the trials lollow:
(1) A 6-week, placebo-controllrial (N:335) compared 3 fixed dosage ranges of ZVPREXA
(5% 2.5, tO% 2.5, and 15% 2.5 mglday 00), 1 dosage range of haloperidol (15 ± 5 mglday on a
BID schedule), and placebo. The 2 higher dosage ranges o1 ZVPREXA were statistically sognmcantly supenor to placebo on the Brief Psychiatric Rating Scale (BPRS) total. the Clinical Global
Impressions • Severity of Illness (CGI·S) scale, and the SPAS positive psychosis cluster. The
hoghest dosage range of ZVPREXA was statistically signnicantly superior to placebo and to
haloperidol on the Scale for the Assessment of Negative Symptoms (SANS). Effocacy of ZVPREXA
generally increased wrth dose. The 5 ± 2.5 mglday dosage range of ZVPREXA was numerically,
but not statistically, signnicantly superior to placebo on SPAS total and other assessments of over·
aNpsychopathology.
(2) A 6-week, placebo-controled lrial (N= 152) compared 2 foxed doses of ZVPREXA ( 1 or
10 mglday OD) and placebo, ZVPREXA, 10 mg/day, was statisticaDy signnicantly superior to placebo on the SPAS total, the BPRS positive psychoSis cluster, the CGI-S scale, the POSitive and
Negabve Syndrome Scale (PANSS) total, the PANSS positive subscale, and the PANSS negative
subscale. ZVPREXA, 1 mglday, appeared to be a ne>-effect dose with no difference, clinically or
statJstically, from placebo on any assessment of psychopathology.
(3) A 6-week. dose comparison lrial (N=431) compared 3 fixed dosage ranges of ZVPREXA
(5 ± 2.5, 10 ± 2.5 and 15 ± 2.5 mg/day 00), ZVPREXA (1 mg/day OD). and haloperidol (15 ±
5 mglday on a BID schedule). There were no statJstically significant differences between groups on
efficaocy measures except for the highest dosage range of ZVPREXA. which was statistocally
significantly superior lo ZVPREXA, 1 mg. on the BPRS positive psychoSis cluster, PANSS posrtove
subscale, and the CGI·S scale.

(4) A 6-week comparator-rontrolled lnal (N=1996, 2:1 randomization, ZVPAEXA : haloperidol)
compared 1 dosage range of ZVPREXA (5 to 20 mglday OD) and 1 dosage range of haloperidol
(5 lo 20 mg/day OD). The arute mean modal doses (for those patients with al least 3 weeks of
treatment) were 13.2 mg/day for ZVPREXA and 11.8 mglday for haloperidol. ZVPAEXA was
statistocally signtficantly superior lo haloperidol on the BPRS total, the BPRS negative psychosis
cluster. the PANSS negative subscale, and the CGI·S scale. ZVPREXA was also stabstoc:ally
sogrnficantly supenor to haloperidol on the Montgomery·Asberg Depression Rating Scale
(MAOAS). The validHy of this scale in patients With schizophrenia. hoWeVer, Is not established
(5) The effeci!Veness of ZVPREXA on long-term therapy, o.e., >6 weeks, was evaluated in
3 double-blind. controlled, extension maontenance trials (of arutelrials 1, 3, and 4 above). Patients
who showed adequate clinical improvement following double-blind arute therapy were allowed to
contonue on "' a double-blind, long-term extensoon mamlenance phase on their arute dosage
regome. Long-term maintenance of treatment response (as defined by continued reduction n sogns
and symptoms sufficient to not requore hospitafozation for psychosis) was compared over tJme
(894 ZVPAEXA·treated patients; median length ol treatment was 237 days). The percentage of
patients maintaln1ng treatment response over one year was compared. ZVPREXA was statistically
sognificantly superior to placebo on the one placebo-controlled lnal and was comparable or sta·
bstically sognifocanlly superior to the active comparator in 3 of 3 actiVe comparator-rontrolled trials.
While the effocecy of ZVPAEXA at a dose of 5 mg/day was not statistically superior to placebo
(see (1)), some individual patients receiving this dose had a good acute response, and were well
maintained during a one year extension phase.
The above trials (including open-label extension) and an additional lrial in geriatric patients with
pnmary degenerative dementia of the Alzhetmer's type constHute the primary database (N:2500
patients treated with ZVPREXA, corresponding to 1122.2 patient-years; N=810 patients treated
with haloperidol, corresponding 1o 193.0 patient-years; N:236 patients treated with placebo,
corresponding to 27.1 patient-years).
INDICATIONS AND CLINIC A L USES
ZVPREXA" (oianzapone) is indicated for the arute and maintenance treatment of schizophrenia
and related psychotoc disorders. In controlled clinical tnals, ZVPREXA was found to improve both
positive and negabve symptoms.
ZVPREXA has been shown to be effeci!Ve n mantainong clinical improvement dumg one year
of contnuabon therapy in patients who had shown an onitlallreatmenl response.
CONTRA IN Dl CATIONS
ZVPREXA• (oianzapone) is contraindicated on those patients with a known hypersensotivrty to the
drug or the excipoenls of the product
WARNINGS
Neuroleptic Malignant Syndrome: In prernarl<eting cfoniCBI tnals there were no reported cases of
NMS in patients receiving ZVPREXA• (olanzapine). However, NMS is a potentially fatal symptom
complex, that has been reported in assoaation with antipsychotic drugs. Clinical mandestations
of NMS are hyperpyrexia, muscle ngodrty, altered mental status. and evidence of autonomic
onstabiloty Qrregular pulse or blood pressure, tachycardoa, diaphoresis, and cardiac dysrhythmoa). Addotoonal signs may include elevated creatone phosphokinase, myoglobinuria
(rhabdomyolysls), and arute renal failure.
The management of NMS should onclude ommediate disconlonualoon of all antipsychotic drugs
including ZVPREXA. intensive monHonng of symptoms and treatment of any associated medical
problems. There IS no general agreement about specific pharmacologicaJ treatment for NMS.
If a patient requores antipsycholic drug treatment alter recovery from NMS, the reintroduction of
therapy should be very carefully consodered, sonce recurrence of NMS has been reported
Tardive Dyskinesia: Tardive dyskinesia (TO). a syndrome consisting of potenlialy orreversible
onvoluntary dysloneuc movements, os assoaaled with the use of antipsychotic drugs. Tardive dys·
kones4a occtJrs more frequently in elderly patients, hoWeVer. patients of any age can be affected.
IS unl<nown whether antipsychotic drugs may differ in theor potential to cause TO. However, dunng
long-term , double-blind extension maonlenance trials (894 olanzapine-lreated patients; median
oianzapine treatment. 237 days). ZVPAEXA was associated with a statistically signifocantly lower
oncodence of treatment emergent dyskonesoa compared to haloperidol.
The risk of developing tardive dyskinesia and the chance of H beoorning irreversible, are
believed lo oncrease as the duration of treatment and the cumulatrve dose of antipsychotic drugs
oncrease. However, the syndrome can develop, although less commonly, alter relatively brief
penods of treatment at low doses. There is no known treatment for established cases ol TO. The
syndrome may rernrt, partially or completely, d antipsycholic drug treatment is withdrawn .
Anbpsychotic drug treatment itself, however, may suppress the signs and symptoms of tardiVe
dyskonesoa, thereby maskong the underlying process.
Given these considerations, ZVPREXA should be prescnbed "' a manner that is most likely to
monimoze the risk of tardive dyskinesia. As with any antipsychotic drug, ZVPREXA should be
reserved for patients who appear to be receivong substanUal benefit from the drug. In such patients
the lowest effeci!Ve dose and the shortest duration of treatment should be sought The need for
contonued treatment shotAd be reassessed periodically.
If sogns or symptoms of tardive dyskines4a appear on a patient on ZVPAEXA, drug discontnua·
bon should be considered. However, some patients may benefit from continued treatment with
ZVPREXA desprte the presence of the syndrome.

n

PRECAUTIONS
Lactose: ZVPREXA• (oianzapine) tablets contain lactose.
Potential Effect on Cognitive and Motor Performance: Because ZVPREXA may cause
somnolence, patients should be cautioned about operating hazardous machinery, including motor
vehiCles , until they are reasonably certaon thai ZVPREXA therapy does not affect them adversely.
Hypotens ion and Syncope: As wrth other drugs thai have high alpha· t adrenergic receptor
blockong actMty, ZVPREXA may onduce orthostatic hypotension, tachycardia, dizziness, and
somebmes syncope, especial!) at the onotoabon of treatment In a clinical trial database of 2500
patients treated with ZVPREXA. syncope was reported in 0.6% (1512500). The risk of orthostatic
hypotensoon and syncope may be mnmozed by initialing therapy with 5 mg OD (see DOSAGE
AND ADMINISTRATION). A more gradual titration to the target dose should be considered
hypotensoon occtJrs. ZVPAEXA should be used with particular caution in patients with known cardiovascular disease (history of myocardial onfarction or ischernoa, heart tailure, or c:onduciJon
abnormalities), cerebrovascular disease, and condHions which would predispose patients to
hypotensoon (dehydration, hypovolemoa, and treatment wrth anbhypertensive medications).

n

Seizures: Conventional neurolepbcs are known lo lower seozure threshold. In clirucal tnals,
seozures have occtJrred in a small number (0 . ~ . 2212500) of ZVPREXA-trealed patients. There
were confooodong factors that may have contributed to the occtJrrence of seizures in many of these
cases. ZVPAEXA should be used cautoously on patients who have a history of seizures or have
condHions associated with seizure or have a lowered seizure threshold.
Transaminase ElevaUons: During prernarl<eting clinicallrials, therapy with ZVPAEXA was assocoated with elevation of hepatic transamonases, primarily ALT (SGPT). Within a clinicallrial data·
base of 2280 ZVPAEXA·trea1ed patients, wrth baseline ALT (SGPT) levels $60 IUA., 5.9%
(t3412280) had treatment-emergent ALT (SGPT) elevations to >120 lUll, 1.9% (4412280) had
elevations to >200 lUll, and 0.2% (512280) had elevaticons to >400 lUlL No patien1s had
values on exoess of 700 lUlL None of the ZVPREXA·treated patients who had elevated lrarosam·
inase values manifested clinical symptomatology associated with liver impairment The maJOrity
of trarosaminase elevations were seen dunng the first six weeks of lrealrnenl. Most elevations were
tranSient (66%) while patients continued on ZVPREXA therapy, or falling (11%) at the last available measurement. Of the 134 ZVPREXA·Ireated patients whose enzyme levels increased to
>120 lUll, 20 discontinued treatment (6 for hepatic, 14 for other reasons) while their ALT (SGPT)
values were stil nsing. In 38 ZVPREXA·Ireated patients woth baseline ALT (SGPT) >90 lUll, none
experienced an elevation to >400 lUlL
. Precauboros should be exerased when usong ZVPREXA on patients with prlH!Xlsting hepatic
disorders. on patients who are betng treated wrth potentJalty hepatotoxic drugs, or treatment·
emergent sogns or symptoms of hepabc ompaorment appear.

n

"FICtitious case, may not be predictive of results in other patients.

Martin has schizophrenia. And
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Introducing P
rZyprexa· (olanzapine),
Making Re-integration the Goal ...

ulfilled desire to be back home.*
When your goal is Re-integration ...

Choose Zyprexa
Novel antipsychotic power for routine use in
the majority of patients with schizophrenia and
related psychoses
Zyprexa ...
• compared to haloperidol offers superior efficacy in acute and
maintenance treatment in both positive and negative symptomst
• is generally safe and well-tolerated§
• offers convenient once-daily dosing at 10 mg*

You and your patients measure success one achievement at a
time. Progress may be modest or great, but every achievement
is counted as a victory toward the goal of re-integration.
t6 week acute phase: Zyprexa (n=1 ,312), 5-20 mglday; Haloperidol (0=636), 5·20 mglday; SPAS Total score p:0015: PANSS polilve
score p:0.056; PANSS negative score p:0.032. Kaplan-Meier survival curve at 1 year: Zyprexa (n><627), 2.5-20 '"9'day;
Haloperidol (n=180), 5-20 mglday, p:0.034.
§The most common adverse events associated with Zyprexa are dizziness, consbpabon, AlT(SGPT) onct81188d, M1911 gain, lllc8llilla,
and postural hypotension. Caution should be exercised in patients With renal and/or hepabc ornpamnent.
tlncrease to doses greater lhan target dose only after clinocal assessment The safety of doses alxNe 20 '"9'day has na1 t..1
evaluated tn clinical tnals. Responding patients should be conbnued at the lowest dose Meded 1o rwnill8ion.

0/anzapine
..,.,lr;;;;• antipsychotic power for,...

For patients who have known or suspected abnormal hepatic function prior to starting
ZVPREXA. standard clinical assessment, including measurement of transaminase levels is rec·
ommended. Periodic clinical reassessment with transaminase levels is recommended for sucl1
patients, as well as for patients who develop any signs and symptoms suggestive of a new onset
liver disorder during ZVPREXA therapy.
Hematologic Indices: In clinical trials, there were no data to suggest ZVPREXA adversely affect·
ed bone marrow function. even in patients with a hiStory of clozapone-associated neutropenia
or leukopenia ZVPREXA was associated With a 5.7". ltiCidence of mainly transient treatment·
emergent elevabons of eosinophil counts above the normal range. Elevations were not associat·
ed With any symptoms, identifiable allergic phenomena. or changes 1n other hematologic indices.
Hyperprofactinemla: As with other diUQS that block doparTwle 02, and/or serotonin 5-HT2 receptors, olanzapine may elevate prolactin levels. Elevabons assoaated with ZVPREXA treatment are
generally mild, and may decline during continued admonlstrabon.
Since tissue culture experiments indicate that approximately one third of human breast cancers
are prolactin dependent in llitro, ZVPREXA should only be administered to patients with previously
detected breast cancer ~ the benefits outweigh the potential risks. cautJon should also be exercised when considering ZVPREXA treatment " pat1811ts With poturtary turnors. Possible manifests·
lions assoaated with elevated prolactin levels are amenormea, galactorrhea, and menoohagl8.
As is common with compounds which stimulate prolacbn release , the administration of olanzapine resutted "' an increase in the incidence of mammary neoplasms "' bolh rats and mice. The
physiological differences between rats and humans with regard to prolactin make the clinical sig·
ntlicance of these findings unclear. To date. neither clinical nor epidemiologocal studies have shown
an associabon between chronic administration of these diUQS and mammary tumorigenesis.
Uric Acid: In the premarketing clinical trial database, ZVPREXA was associated with mild eleva·
lions of unc acid "' some patients. However, only 1 ZVPREXA-treated patient experienced treat·
ment-emergent gout, and the baseline uric acid concentration for this patient was at least as large
as att concentrations observed while the patient was rec:eMlg ZVPREXA
Weight Gain: Olanzapine was associated with weight gam dunng clirucal trials. Patients treated at
higher doses ( 15 ± 2.5 mglday) had the greatest mean weight Qalll. However, a categorization
of patients at baseline on the basis of body mass Index (BMI) revealed a significantly greater
effect in patients with low BMI compared to normal or overweight patients. Using pooled data
from patients treated with olanzapine over the dosage range of 5 mg to 20 mg per day, weoght gain
tended to level off at 6 to 8 months of treatment. With a mean gam of 5.4 kg.
Antiemetic Effect: Consistent with its dopam111e antagonost effects, olanzapine may have an
antiemetic effect. Such an effect may mask signs of toxicity due to overdosage of other drugs, or
may mask symptoms of disease suc11 as brain tumor or intestinal obstnuction.
Body Temperature Regulation: Disruption of the body's ability to reduce core body temperature
has been attributed to antipsychotic agents. Appropriate care is advised when prescribing
ZVPREXA for patients who wil be experiencing conditions whiCh may contribute to an elevation of
core temperature, eg. exercising strenuously, exposure to extreme heat, receiving concomitant
medicat100 with anticholinergic activity, or belllQ SlJbtecl to dehydrabon.
Suicide: The possibility of suicide or attempted suiCide os A1herent in psychosis, and thus close
supervision and appropriate clinical mar13gement of hogh-nsk patients should accompany drug
therapy.
Drug Interactions: Given the primary CNS effects of ZVPREXA, caution should be used when H is
taken in combination with other centraUy-acllng diUQS and alcohol. As rt exhibits m vrtro dopa·
mine antagonism, ZVPREXA may antagonize the effects of levodopa and dopamine agonists.
Because of its potential for Inducing hypotensoon. olanzapone may enhance the effects of certain
antihyperterosive agents.
Poterrtial for Other DNQS to Affect ZVPREXA: The metabolism of olanzapine may be induced by
concomHant smoking, or carbamazepine therapy. The concomitant administration of actiVated
charcoal reduced tha oral bioavailabiiHy of ZVPREXA by 50'lo to 60%. Single doses of antacid (alu·
minium, magnesium) or cimetidine did not affect the oral bioavailabiiHy of ZVPREXA. Agents that
induce CYP 1A2 sucl1 as omeprazole may increase clearance of olanzapine. Conversely, inhibitors
of CYP1 A2 (e.g. fluvoxarnine) could potentially inhibH elimination of olanzapine. However, as olan·
zapine is metabolized by multiple enzyme systems, inhibH100 ol a single enzyme may not appreciably decrease olanzapine clearance.
Potential for ZVPREXA to Affect Other Drugs: In clinical tnals with single doses of ZVPREXA, no
inhibition of the metabolism of 1mipramine/desipram1ne (P450-CYP206), war1arin (P450CYP2C9), or diazepam (P450-CYP3A4) was eVIdent. ZVPREXA showed no Interaction when
coadministered with lithium. Also, in in vitro studies With human ITliCfOSOfTleS, olanzapine showed
little potential to inhibit cytochrornes P450-CYP1A2, -CYP2C9, -CYP2C19, -CYP206, and
-CYP3A4 (see PHARMACOLOGY). Oianzapone IS thus unlikely to cause clinically Important
drug-drug ~nteracbons mediated through the metaboliC routes ouU'ned above. However, the
possibility that olanzapine may alter the metabolism of other drugs, or that other drugs may alter
the metabolism of olanzapone, should be considered when prescribing ZVPREXA
Pregnancy: There are no adequate and weU-controlled studies in pregnant women. Patients
should be adviSed to notily their physiCian ~ they become pregnant or Ulland to become pregnant
during treatment with ZVPREXA Because human expenence 1n pregnant females is irTll ed, this
drug should be used in pregnancy only ~ the potential benefrt justifies the potential risk to the fetus.
Labor and Delivery: Parturiticlll in rats was not affected by olanzapine. The effect of ZVPREXA
on labor and delivery in humans is not known.
Lactation: Oianzapine was excreted in m~k of treated rats during lactabon. ij is not known ~ olanzapine is excreted '" human milk. Patients should be advised not to breast feed an infant ~ they
are taking ZVPREXA
Geriatrics: The number of patients 65 years of age or over, With schizophrenia or related disor·
ders, exposed to ZVPREXA. during cliniCal tnals was lirnHed (N=44). caution should thus be exercised with the use o1 ZVPREXA in the -11y patient, recognmg the more trequem hepalx:, renal,
central nervous system. and cardiovascular dyslunciJons, and more frequent use of concomitant
medocabon Ill this population (see DOSAGE AND ADMINISTRATION).
Children: The safety and effiCaCY of ZVPREXA in children under the age of 18 years have not
been established.

Renal and Hepatic Impairment Small singie-<lose cl1n1Cai pharmacology studies (see PHAR·
MACOLOGY, Special Populations), did not reveal any major alterations in olanzapine pharmacOkinetics in subjects with renal or hepatic impairment. Given the limHed clinical experience with
ZVPREXA 1n pabents with these conditions, caution sho!Ad be exercosed (see DOSAGE AND
ADMINISTRATION).
Use in Patients with other Concomitant Illness: Clinical expenence with olanzapine in patients
with concomitant illness is limHed. caution is thus advised when using ZVPREXA in patients with
diseases or conditions that could affect the metabolism or the pharmacodynamic activHy of olan·
zapine (see PHARMACOLOGY, Pharmaookinetics, and DOSAGE AND ADMINISTRATION).
ZVPREXA has not been evaluated in patients With a recent hiStory of myocardial infarction or
unstable heart disease. Patients with these concibons were excluded lrom prernarketing cliniCal trials.
As ZVPREXA demonstrated anticholinergic actJVity m vitro, caution is advised when prescribing for
patients with symptomatic prostatic enlargement, narrow-angle glaucoma or paralytic ileus and
related conditions.
In clinical trials, a single case of pre-existing 1ntercranial hypertensoon exacerbated.
ADVERSE REACTIONS
The stated frequencies of adverse events represent the proportion of individuals who experienced,
at least once, a treatment-emergent adverse event of the type listed. An event was considered
treatment-emergent ~ H occurred for the first time or worsened while receiving therapy following
baseline evaluation. tt is important to emphasize that although the events were reported during
therapy, they were not necessarily caused by the therapy.

The prescriber should be aware that the figures in the tables and tabulations cannot be used
to predict the incidence of side effects in the course of usual medical practice where patient char·
acteristics and other factors differ from those that prevailed in the clinical trials. Similal1y, the crted
frequencies cannot be compared with figures oblained from other clinical investigations involving
different treatments, uses, and investigators. The fiQtJres crted, however; do provide the prescnb'"9 physician with some basis for estimating the relative contribution of drug and nondrug factors
to the side effect incidence in the populations studied.
Commonly Observed Adverse Events In Placebo-Controlled Clinical Trials: The foliowlng
treatrnerrt-emergent adverse events, derived from Table 1, commonly occurred during acute thor·

apy with ZVPREXA• (olanzapine) \lllCidence of at least 5%, and more than double the Incidence
observed with placebo): dizziness, constipation, All (SGPT) increased, weight gain, akalhisia, and
postural hypotension.
Adverse Events Associated with Dlscontlnuation: Short· Term, f'lacebo.Contro/led Qimcal
Trials: There was no stalisticaly significant difference in rates of discontinuation of ZVPREXA or
placebo attributed to adverse events. Overall, 5% of ZVPREXA·treated patients disconbnued
treatment for adverse events compared with 6% of placebo-treated patients. Discontinuations due
to All (SGPT) elevations; however, were considered to be drug related (2% for olanzapine versus
0% for placebo) (see PRECAUTIONS).

Short· Term, ActNI>-Controlled C/inicaJ Trials: Of the 1796 ZVPREXA·treated patients 1n cornparatrve clinical trl8ls with haloperidol, 98 (5%) discontinued treatment for adverse events compared
with 66 of 810 (8%) haloperidol-treated patients
Overal Integrated Safely Database: In a prernarketing clinocal trl81 database of 2500 ZVPREXA·
treated patients, 14.9% (37212500) discontinued for an adverse event About hall (1831372) of
these discontinuations were associated with the underlying psychopathology. Other adverse
events most commonly ('lllCidence of 0.5'lo • 0.6%) reported as the reason for discontinuabon

among olanzapine-treated patients were: All (SGPT) increased, uruntended pregnancy, creabne
phosphokinase increased, and convulsion.

Incidence of Adverse Events in Placebo-Controlled Clinical Trials: Table 1 enumerates the
lllCidence, rounded to the nearest peroent of treatment-emergent adverse events that occurred
during acute therapy (up to 6 weeks) of schizophrenia "' 1% or more of patients treated w-th
ZVPREXA (doses ;,2.5 mg/day) where the incidence in patients treated with ZVPREXA was
greater than the ltiCidence in placebo-treated patients.
TABLE 1 :
Treatment-Emergent Adverse Events
Incidence In Placebo-Controlled Clinical Trials • Acute Phase•
Peroentage of Patients Reporting Event
Body System/Adverse Event
ZVPREXA
Placebo
(N--248)
(N= 118)
Body As a Whole
17%
15%
Headache
10%
Pain
9%
Fever
3%
5%
2%
Abdominal pain
4%
Back pain
4%
3%
Chest pain
4%
2%
Neck ngidHy
1%
2%
0%
Intentional injury
1%
Cardiovascular System
2%
Postural Hypotension
5%
1%
Tachycardl8
4%
1%
Hypotension
2%
Digestive System
3%
Constipation
9%
4%
Dry mouth
7%
1%
Gamma glutamyl transpeptidase increased 2%
1%
2%
Increased appe!He
Hemic and lymphatic
leukopenia
1%
0%
Metabolic and Nutritional Disorders
SGPTIIlCreased
3%
8%
1%
6'lo
Weight gamt
0";.
Edema
2%
0%
Peripheral edema
2%
0";.
SGOT increased
2"o
1••
Crealllle Phosphokinase increased
O"o
Musculoskeletal System
2"o
Arthralgia
3"o
1'lo
Joint Dtsorder
2"o
Twrtchong
1'lo
2"o
Nervous System
15%
26%
Somnolencet
17%
Agitation
23%
19'lo
Insomnia
20%
14%
16%
Nervousness
14%
15%
Hostility
4%
11%
Dtzzinesst
8%
9%
Anxiety
4%
Personality disorder
8%
1%
5%
Akalhisiat
3%
4%
Hypertonia
10'0
4%
Speech Otsorder
Tremor
4...
3"o
()%
Amnesia
2%
()%
Drug Dependence
2"o
O"o
Euphona
2"o
1'lo
O"o
Neurosis
Respiratory System
10%
6%
Rhinitis
3%
Cough lllCI'eased
5%
3%
5%
Pharyngitis
Skin and Appendages
0%
2%
Fungal Dermatitis
1%
Vesiculobullous rash
2%
Special Senses
4%
5%
Amblyopia
1%
Blepharitis
2%
1%
Eye Disorder
2%
1%
0%
Corneal lesion
Urogenital System
0%
2%
Menstrual Dtsorde<l
"The foflowtng events had an incidence equal to or less than placebo: abnormal dreams, acct·
dental intury, anorexia, apathy, asthenia, cogwheel rigidity, confusion, conjunctivitis, depression,
diantlea, dysrnenontoeai. dyspepsia, ecchymosis, emotional labiiHy, hallucinations, hyperkinesia, hypertension, hypokinesia, libido increased, myalgia, nausea, paranoid reaction, paresthesia, pruritus, rash, schizophrenic reaction, sweating, thinking abnormal, tooth caries, vaginitis;,
vomiting.
tStatistlcatty signif1C811tly more frequent in patients treated with ZVPREXA than in patients treated
with placebo.
t:Denorninator used was for females only (N=41 ZVPREXA; N=23 Placebo).

Incidence of Weight Changes In Placebo-Controlled Clinical Trials: During acule therapy (up
to 6 weeks) in controlled clinical trials comparing lYPREXA with placebo in the treatment of schizophrenia. the percentages of patients with weight gain ~ 7% of base~ne body weight at any time
were 29% for lYPREXA and 3% for placebo, which was a statistically significant difference. The
average weight g<Pl during acule therapy in patients treated with lYPREXA was 2.8 kg. However,
a categorization of patients at baseline on the basis of body mass index (BMI) revealed a significantly greater effect in patients with low BMI compared to normal or overweight patients. In longterm extension trials weight gain tended to level off after 6-8 months of treatment, with an average
ga1n of 5.4 kg (see PRECAUTIONS).
Incidence of Vital Sign Changes In Placebo-Controlled Clinical Trials: In Placebo-Controlled
clinical trials , orthostatic hypotension (greater than 30 mm decrease in systolic blood pressure)
occurred with an incidence of 5% in olanzapine-treated patients compared to 2% in placebo-treated patients (vital sign measurements collected only after 3-7 days of lYPREXA treatment).
Olanzapine was assoaated with a mean baseline to endpoint increase in heart rate of 2.4 beats
per minute compared to no change among placebo-treated patients (see PRECAUTIONS).
Incidence of Laboratory Changes In Placebo-Controlled Clinical Trials: Olanzapone is assoaated with asymptomatic InCreases in SGPT, SGOT, and GGT (see PRECAUTIONS). Olanzapine is
also associated with generally mild increases in serum prolactin, which usually decreases with
continued drug treatment. Olanzapine is also associated with asymptomatic elevations ol
eosinophils and uric acid (see PRECAUTIONS). and with decreases in serum bicarbonate.
Incidence of ECG Changes In Placebo-Controlled Clinical Trials: Between-group comparisons
for pooled placebo-controlled trials revealed no statisticatly significant olanzapinelplacebo differences 1n the proportions of patients experiencing potentially important changes in EGG parameters, including OT, OTc. and PR 111tervals.
Dose-Dependent Adverse Events In Fixed-Dose Clin ical Trials: Dose-relatedness of adverse
events was assessed us1ng data from a clinical trial with a fixed dosage range. Table 2 enumerates the treatmeni-Mlergenl adverse events 1n which there was a statistically significantly
incre8Sing dose response in this clinical trial.
TABLE 2 :
Dose-Dependent Adverse Events In a Fixed Dosage Range,
Placebo-Controlled Clinical Trlat•

Body System/
Adverse Event
Digestive System
Constipation
Nervous System
Abnormal dreams

Dizziness
Somnolence

Placebo
(N--68)

Percentage of Patients Reporting Event
lYPREXA
lYPREXA
lYPREXA
5 % 2.5 mg/day 10 ± 2.5 mg/day 15 ± 2.5 mg/day
(N=65)
(N=64)
(N=69)

0%

6.2%

9.4%

14.5%

0%
2.9%
16.2%

0%
7.7%
20.0%

1.6%
9.4%
29.7%

4.3%
17.4%
39.1%

1.5%

3.1%

1.6%

10.1%

Hypotension and circulatory collapse should be treated with appropriate measures such as
JOtravenous fluids and/or sympathomimetic agents such as norepinephrine (do not use epinephrine. dopamine or other sympathomimetic agents with beta-agonist activity since beta stimulation
may worsen hypotension in the setting of alpha blocl<ade induced by lYPREXA). Cardiovascular
monrtonng should commence immediately and should include continuous electrocardiographic
monrtoring to detect possible arrhythmias.
Close medical supervision and monitoring should conbnue until the patient recovers.
DOSAGE AND ADMINISTRATION

(see also CLINICAL PHARMACOLOGY)
Adults: lYPREXA" (ofanzapine) should be administered on a once-a-day schedule without regard
to meals, generally beginning with 5 to 10 mg. with a target dose of 10 mglday within several
days. Furiher dosage adjustments, ~ indicated, should generally occur at intervals of not less than
1 week. since steady state for lYPREXA would not be achieved for approximately 1 week n the
typical patient When dosage adjustments are necessary, dose increments/ decrements ol 5 mg
00 are recommended. An increase to a dose greater than target dose of 10 mglday ~. e ., to a dose
of 15 mglday or greater) is normally recommended only after clinical assessment
In clinical trials a dose range of 5-20 mglday was studied (see CLINICAL TRIALS). The safety
and etfJCaC)I of doses above 20 mglday have not been evaluated.
The elderly or debilitated patient: In clinical trials, 44 patients with schizophrenia or related disorders, 65 years of age or over. were treated with lYPREXA (5-20 mg daily) (see PRECAUTIONS;
see also PHARMACOLOGY, Special Populations). Given the ~m~ed experience with lYPREXA
in the
and the higher incidence of concomitant illness and concomitant medication in this
population, lYPREXA should be used with caution .
The recommended starling dose IS 5 mg in patients who are
debilitated, who have a
predisposition to hypotensive reactions, who otherwise exhibit a combination of faclors that may
resu~ 1n slower metabolism of lYPREXA (e.g., nonsmoking female patients), or who may be
pharmacodynamically more sensitive to lYPREXA. When indicated, dose escalation should be
performed with caution in these patients.

-rly.

-11y.

Patients with Hepatic and/or Renal Impairment: As clinical experience is lacking in these
patients, the lower initial starting dose and slower titration to inibal target dose should be considered. Furiher dose escalation, when indicated. should be conservative (see PRECAUTIONS; see
also PHARMACOLOGY, Special Populations).
Maintenance Therapy: It is recommended , that responding patients be continued on lYPREXA
at the lowest dose needed to mainllm remission. Patients should be reassessed penodically to
determme the need for ma1ntenance treatment While there is no body of evidence available to
answer the question of how long the patient should be treated with lYPREXA, the effectiveness of
maintenance treatment is wen established for many other antipsychotic drugs.
PHARMACEUTICAL INFORMATION
DRUG SUBSTANCE :

Respiratory System

Pharyngitis

'Fungal dermatitis was also reported with a statistically sigrificantly increasing dose response,
but is not included as a drug cause was remote.

Partonsonism'
Akathisia2

15%

23%

lYPREXA"

Proper Name:

Olanzapine

Chemical Name:

Incidence of Treatment-Emergent Extrapyramidal Symptoms in Placebo-Controlled Trials:
Table 3 enumerates the percentage of patients with lreatmenl-<!1118rgent extrapyramidal symptoms
as assessed by categorical analyses of formal rating scales during acute therapy in a controlled
clinical trial comparing ofanzapine at 3 fiXed dosage ranges with placebo in the treatment of
schizophrenia.
TABLE 3 :
Treatment-Emergent Extrapyramidal Symptoms Assessed By Rating Scales
Incidence In A Axed Dosage Range, Placebo-Controlled Clinical Trial -Acute Phase•

Placebo

Trade Name:

2-Methyl-4-(4-methyl-1-piperazinyf)-1 OH-thieno[2.3-b) (1 ,5)
benzodiazepine

Structural Formula:

Percentage of Patients
lYPREXA
lYPREXA
lYPREXA
5 ± 2.5 mglday 10 ± 2.5 mglday 15 ± 2.5 mglday
14%
16%

12%
19%

14%
27%

sign~icanl differences.
'Percentage of patients with a Simpson-Angus Scale total score >3.
Percentage of patients with a Sames Akathisia Scale global score ~-

'No statistically

Molecular Formula:

2

Table 4 enumerates the percentage of patients with treatmenl-<!1118rgent extrapyramidal symptoms
as assessed by spontaneously reported adverse events during acule therapy in the same controlled clmical trial comparing olanzapine at 3 fixed dosage ranges with placebo in the treatment of
schizophrenia.
TABLE 4 :
Treatment-Emergent Extrapyramidal Symptoms Assessed by Adverse Events
Incidence In a Axed Dosage Range, Placebo-Controlled Clinical Trial -Acute Phase

Extrapyramidal Symptoms
Dystonic eventst
Partonsonism evenlsl
Akath1s13 events§
Dyskinetic eventsll
Residual eventsl
Any extrapyramidal event

Placebo
(N=68)
1%
10%
1%
4%
1%
16%

Percentage of Patients Reporting Event
lYPREXA
lYPREXA
lYPREXA
5 ± 2.5 mglday 10 ± 2.5 mglday 15 ± 2.5 mg/day
(N=65)
(N=64)
(N=69)
3%

8%
5"'0%
2%
15%

2%
14%
11%'
2%
5%
25%

3%

20%

tO%•
1%
1%

Molecular Weight:
Description :

pK.:
Melting Point:

312.44
Olanzap!ne is an antipsychotic agent of the thienobenzodiazeptne
class. It is a yellow crystal1ine solid, which is soluble in
n-Propanof and practically insoluble in water.
5.00 and 7.40 in DimethyHormamide/Water (60:40. v/v)
195 ± 2"C
COMPOSITION :

Each lYPREXA (olanzapine) tablet contains the equivalent activity of 5 mg (16 ~tmof) , 7.5 mg
(241!mof). or 10 mg (32~tmof) of olanzapine. Inactive ingredients include camauba wax, color mixture white (hydroxypropyl methytcel1ulose, titanium dioxide, polyethylene glycol, and polysortlate
80), crospovidone, FD&C Blue No. 2 Aluminium Lake, hydroxypropyl cellulose, hydroxypropyt
methylcellulose, laclose, magnesium stearate. and microcrystaHine cellulose.

J2%•

• Statistically signifiCantly different from placebo.
t Patients with the following COSTART terms were counted in this category: dystonia, generalized
spasm, neck rigidity. oculogyric crisis, opisthotonos, torticollis.
i Patients with the following COSTART terms were counted in this category: akinesia. cogwheel
ngldity. extrapyramidal syndrome, hypertonia, hypokinesia, masked facies, tremor.
§ Patients with the following COSTART terms were counted in this category: akathisia, hypert<ines&a
II Patients with the following COSTART terms were counted in this category: buccoglossal syndrome. ctloreoathetosis, dyskinesia, tardive dyskinesia.
I Patients with the following COSTART terms were counted in this category: movement disorder,
myoclonus. lwi1ching.

C,,.H..N,S

STABILITY AND STORAGE RECOMMENDATIONS :
Store tablets at 20· ·25•c . Protect from light and moJSture.
AVAILABILITY OF DOSAGE FORMS :
All tablets are wh~e . round , film-coated, and imprinted in blue ink with "LILLY" and the tablet idenbflcabon code. Each strength is available in amber HOPE bollles of 60 tablets.
TABLET STRENGTH
5mg

7.5mg

Tablet No.

4115

4116

4117

Imprint

LILLY
4115

LILLY
4116

LILLY
4117

SYMPTOMS AND TREATMENT OF OVERDOSAGE
Experience with lYPREXA• (ofanzapine) in overdosage is im~ed. In clinical trials, accidental or
Intentional acute overdosage of lYPREXA was identified in 67 patients. In the patient taking the
largest identified amoun~ 300 mg. the only symptoms reported were drowsiness and slurred
speech. In the lim~ed number of patients who were evaluated in hospitals, including the patient
taking 300 mg, there were no observations indicating an adverse change in laboratory analyles or
EGG. Vllal signs were usually within normal limits following overdoses.
Based on animal data, the predicted symptoms would reflect an exaggeration of the drug's
known pharmacological actions. Symptoms may include somnolence. mydriasis, blurred vision.
respiratory depression. hypotension, and possible extrapyramidal disturbances (see also ANIMAL
TOXICOLOGY).
There is no specffic antidote to lYPREXA; therefore, appropriate supportive measures should
be initiated. The possibility of multiple drug involvement should be considered.
In case of acule overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation. The use of activated charcoal for overdose should be considered
because the concomitant administration of activated charcoal was shown to reduce the oral
bioavailability of lYPREXA by 50% to 60%. Gastric lavage (alter intubation, ~ patient is unconscious) may also be considered.

10mg

Product Monograph available on request. October 15 , 1996 .
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STRESS

REACTIONS OF THE DISTAL
RADIAL EPIPHYSEAL
PLATES IN YOUNG GYMNASTS
by Lynda Newkirk, Meds 2000

ABSTRACT
his paper is a report on stress injuries to the distal
radial epiphyses of young gymnasts. These injuries
are common in young gymnasts as a result of the
repetitive, upper-limb weight-bearing characteristic of the
sport. The topic is introduced with reference to the case of
a n eight-year-old gymna t with damage to the dis tal
epiph y seal plate of her left radius. Pathogenesis,
diagnosis, treatment, epidemiology, etiology, prognosis,
implications, and prevention of stress injuries to the distal
radial epiphyses are discussed.

T

INTRODUCTION
As a result of upper-limb weight bearing, the wrists
of young gymnasts are exposed to unusually large
amount of stress. The stress from repetitive, high-impact
loading may damage their distal radial epiphyseal plates.
This damage may occur as a stress fracture, or as a stress
reaction characterized by irregularity of the metaphyseal
margin, widening, cystic changes, and sclerosis of the
epiphyseal plate Y Damage to the epiphysis warrants
concern as i t may lead to premature closure of the
epiphyseal plate and disrupted growth. 'u.• It is important
tha t gymnastics coaches, parents, and physicians
understand the risks, implications, and symptoms of
these stress injuries, in order that any such injury be
recognized and treated early. The goal of this paper is to
provide information on all aspects of stress injuries to the
distal radial epiphysis.
CASE STUDY
In February 1995, an eight year-old eli te, female
gymnast presented with left wrist pain. In January 1994,
the gymnast fell off the uneven parallel bars and landed
on an outstretched arm, forcing her wrist into
hyperextension. Plain film radiographs showed a Salter
Type II fracture of the distal radius. The fracture was
treated by means of cast immobilization for three weeks.
Repeat x-rays taken at the end of the month showed a
small amoun t of periosteal bone forma tion over the
dorsal surface of the radius, and otherwise little change.
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Human Kinetics degree at the University of British
Columbia.

The injury occurred during the athlete's fourth year
of participation in gymnastics. She was also involved in
dance and karate . At the time of the injury, she was
training at gymnastics for approximately 18 hours per
week. Following the removal of her cast, the gymnast did
ph ysiotherapy and gradually, over a period of one
month, returned to her full training schedule. In January
of 1995, while training 18-20 hours per week, the gymnast
w as experiencing wrist pain during workouts . She
noticed a bump on the dorsum of her wrist. Repeat x-rays
showed irregularity of the epiphysis and slight dorsal
tilting of the distal radius. The radiograph also showed
slight attenuation of the ulnar aspect of the epiphysis,
suggesting disturbed growth. At this point, the gymnast
presented at the Allan McGavin Sports Medicine Centre.
The physical exam showed the following . The left
elbow had full, pain-free range of motion. The left wrist
had full range of motion, with mild dorsal-radial
swelling. The gymnast had full power, and no pain on
forced flexion or extension. She did not experience pain
during normal, daily activities. There was full
neurovascular function. The physician reviewed the
results of the radiographs and noted the indications of
damage to the growth plate.
Treatment involved reducing training to 10 hours per
week and starting a physiotherapy program focusing on
wrist strength and flexibility. The gymnast began to use a
rigid wrist brace during activity, and ice to reduce pain
and swelling post-activity. It was recommended that if
pain continued despite these measures, she should
terminate her participation in gymnastics and place more
emphasis on dance. It was also recommended that if her
condition improved and she was able to increase her
training pain-free, she should train less than 12-14 hours
per week. Upon re-examination in September of 1995, she
reported that training for three consecutive days
aggravated her wrist. She could, however, train for 3
hours a day on alternate days (a total of 12 hours per
week) without any discomfort.

DISCUSSIO N
PATHOGENESIS
The epiphyseal plate is a cartilaginous disk between
the epiphysis and metaphysis. Here cartilage cells
proliferate and calcify during endochondral ossification.
The cartilage of the epiphy eal plate is one of the weakest
skeletal structures in the young athlete. It is estimated to
be 2 to 5 times more likely to sustain injury than the joint
capsule and other ligaments. 5 Consequently, it is
susceptible to both acute and chronic injuries. When
fractured, the epiphyseal plate tends to separate between
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the calcified and uncalcified cartilage at the metaphyseal
junction. This area is avascular, and consequently, there
tends to be a limited amount of swelling a ociated w ith
its fracture.6 When injured, the epiphy eal plate tends to
widen due to continued production of cartilage cells
despite disturbed bone formation .6 Other stress-related
changes include cystic changes (usually on the
metaphy eal aspect of plate), clerosis, irregularity of the
metaphyseal margin, widening of the epiphysis, and a
haz y appearance of the ep iphyseal plate on
radiographs.1.2
DIFFERENTIAL DIAG NOSIS
In diagnosing chronic wrist pain in a young gymnast
one must consider a number of possible injuries. Some of
the e include stress reaction or stress fracture of the distal
radial epiphysis, ligament injury, chondromala cia,
tendonitis, degenerative joint disease, stres fracture of the
radius, ulna, or a carpal bone, tumour, cartilage damage,
and damage to the triangular fibrocartilage complex. The
phy ical exam may enable the physician to diagnos the
presence or absence of tendonitis; however, fur ther
diagnoses will require investigative techniques. The plain
film radiograph may not how stress fractures, but it will
show signs of stress reactions in the epiphyseal plate. It has
been suggested that information from a technetium-99
bone scan is of little use in the diagnosis of epiphy eal
plate injuries: A normal epiphyseal plate ha high uptake,
and injured epiphyses have been found to show uptake
which is normal for the patient' ageY However, the bone
scan ma y be useful in eliminating other possible
diagnoses . Mandelbaum et al. s uggest that MRI is
particularly useful in the diagnosi of gymnastic w rist
injuries as it effectively differentiates between and shows
damage to various types of tructures and tissues. 8
A diagnosis of a stres fracture or stres reaction of the
distal radial epiphyseal plate can be made based on the
following : exposure to a s tres s mechanism , such as
repetitive weight-bearing, localized pain and tenderne
over the distal radial epiphy i , pain in response to forced
dorsiflexion and ometimes with radial or ulnar deviation,
minimal swelling, and radiographs showing a fracture or
other stress related changes as described previously.2 The
gymnast in this case study had a history, physical findings,
and radiograph s con i tent w ith disruption of the
epiphyseal plate as a re ult of an acute fracture of the
epiphysis and continued expo ure to stress.

TREATMENT
Treatment of injuries to the distal radial epiphyseal
plate hould begin con erva ti vely, including rest from
weight-bearing, non-steroidal anti-inflammatory drugs,
physical therapy using multiple modalities, and ice. Some
injuries may require temporary cessation of gymna tics
and immobilization.8 A a guideline, weight-bea r ing
should be avoided until the wrist is no longer tender to
touch and there is no pain with forced range of motion,
especially in dorsiflexion. 2 The athlete should undertake a
strengthening program for upper body and wrists,
keeping activity within a pain-free limit. Return to activity
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should be gradual and progressive, allowing time for the
body to adapt to stress. 2 To protect the wrist from further
damage, the wrist can be taped, or the gymnast can be
fitted with a rigid wrist brace. These methods will help the
gymnast to avoid excessive hyperextension of the wrist.
EPIDEMIOLOGY
A tudy of 100 provincial and national level gymnasts
showed a high injury rate amongst the participants, with
155 acute and 124 chronic injuries sustained over 40
months. 9 In this study, 4.5% (7) of the acute injuries were
fracture of the forearm or wrist, and 1.6% (2) of the
chronic injuries were distal radial stress fractures. Despite
having a high injury rate, the sport of gymnastics is very
popular, with an estimated 600,000 participants in the
United States alone. 2
Recently, there has been a trend toward early
participation in gymnastics which has sparked special
concems. 2 Prepubescent athletes have open growth plates
which are susceptible to damage. This damage may have
significant long-term effects.
Damage to the distal rad ial epiphysi ha been
identified as a common problem for gymnasts. Stress
changes of the distal radial epiphyseal plates were obvious
in 10% of gymnasts at the World Champion hip
Gymnastics Competition in Rotterdam in 1987/ and in 11
of 21 (42%) high performance gymnasts studied by Roy. 2
Epiphyseal plate fractures are most often reported in
competitive gymnasts, but al o occur in individuals at
lower skilllevels. 10
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AETIOLOGY
Factor related to the occurrence of injuries to the
di tal radial epiphysis in gymnasts include the nature of
the skills and the sport, the amount of exposure, and the
equipment.
Many gymnastic kills involve high-impact loading
on the upper extremities. For example, the compressive
ground reaction forces experienced during a back
handspring (a fundamental and frequently repeated skill)
may be up to 2 .4 times bod y weight. ' Repeated
compre sive forces have been indicated as the primary
cau e of chronic wrist injuries in gymnasts. 7-" Other
contributing factors include a combination of
hyperextension and ulnar deviation during vaulting and
tumbling (especially during skill in olving rotation or
twi ting), and the torques applied through the wrist
during balance beam and pommel hor e activitie . In
the e activitie the hands are fixed while the rest of the
body rotates around them .2•10 Many gymnastics skills
involve flight. The nature of these flight moves favour the
prepubescent gymnast. 4 This has resulted in earl y
participation, with young gymnasts training up to thirty
hours per week and exposing their growing bones to high
levels of repetitive physical loading.24 Consequentl y
there is a high risk of growth plate injuries in young
gymnasts.

Section

Gymnastics i by nature a repetitive sport. Gymnasts
repeat skills and routines time and time again, striving for
perfectionY 0 A a re ult, their bodies experience repetitive
rnicrotrauma. This trauma may result in stress fractures.
Fractures of the distal radial epiphyses of gymna t are
commonly stress fractures cau ed by overuse/ ·" but can
also re ult from acute injury, such as in this case where
the gymnast fell onto an out tretched arm. An injury
whose onset is acute may be aggravated and kept from
healing by continued exposure to stress. Some exerci e
has been found to be beneficial, promoting bone growth
and hypertrophy, but the inflammation, disruption of
normal growth, and degenerative changes in the bone of
competitive gymnasts show that the e athletes' bodies are
being stressed beyond their tolerance level. 5 The
epiphy eal plate is a weak area of growing bone and is
consequently a common site of injurie .5
Injuries to the distal radial epiphyses of gymnasts
were found to be related to exposure. Literature citing
wrist pain in gymnasts describe pain occurring, for the
most part, in gymnasts training between 15 and 30 hours
per week_I.2.3.4.s The risk of injury was found to be directly
proportional to the skill level." This was suggested to be a
result of increased training hours and the execution of
riskier and more difficult kills at higher levels of
training.II
Equipment was al o indicated as a contributing factor
to wrist injurie . It was sugge ted that the use of soft mat
may exaggerate dor iflexion. 2 Also, the use of dowel grips
on bars transfers forces from the hands to the wrists. 7· ' 0
Floor exercise, beam, and pommel horse are most often
indicated as causing pain, likely as a result of the torques
and forces applied through the wrists during these
activitie .2.•
PROG NOSIS, IMPLICATIONS, A D PREVENTION
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Wrist pain results in loss of training time and
consequently decreased performance. 8 More eriou ly,
injurie to the distal radial epiphysis may result in
premature closure of the epiphyseal plate and / or
di ruption of growth.'.2..34 With ongoing, normal growth
of the ulna, this may lead to po itive ulnar variance. In
current literature there is admitted uncertainty
concerning whether or not the exposure of gymnasts'
wrists to repetitive microtrauma will result in permanent
damage, and at what level of training the stress becomes
too much for the bones to handle. However, studies of
w orld-class and collegiate gymnasts show that both
adolescent and adult gymnast have highly significant
levels of positive ulnar variance when compared to nonathlete control groups. '-" This uggests that participation
in competitive gymnastic at the collegiate and
international level does disrupt the growth of the radius,
and that thi damage is long-term. Furthermore, positive
ulnar variance has been implicated as a predispo ing
factor in damage to the triangular fibrocartilage, ulnar
impaction yndrome, cystic changes in the triquetrum,
chondromalacia, degenerative arthritis of the ulnar
compartment, and osteomalacia of the ulnar carpals.'.2.s
We can therefore conclude that damage to the distal
radial epiphysis in g ymnasts is a serious injury with
potentially life-long consequences.
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On a more positive note, it ha been found that if
the growth plate injury is diagnosed early and the
athlete responds quickly with conservative treatment,
the prognosis for recovery is very good. 2
Stress reaction to the distal radial epiphys s of
gymnasts are a small part of a much larger issue. They
reflect phy ical tres . Young gymna t al o experience
emotional stress associated with learning high-risk
moves, travelling, and competing . They are under
inten e pressure to win brought upon by their coaches,
their parents, and society. 12 We mu t ask ourselves if
this is right. Should children be exposed to this
magnitude of physical and emotional stress? How much
competition and training is too much? Should children
participate in a sport at a level which may result in lifelong damage? Would these children be better off
participating in a variety of sports? 12 What can we do to
help? These are difficult questions to an wer. Society
put a great deal of emphasis on winning, and winning
major athletic event i associated with much pre tige.
Society's "win at all co ts" attitude would be hard to
change. 12
If we are unable to change the outcome-oriented
approach to athletics, perhaps we can at least control
the process of training and reduce the number of
injuries. This prevention will begin with the education
of coaches, parents, and gymnasts regarding the risks
associated with gymnastics and how they ma y be
avoided. Proper conditioning programs which develop
strength and flexibility should be implemented a t all
levels of training. 9 Increases in training should be

L

gradual and cyclic in nature, allowing the body time to
adapt to new stresses. Gymnasts with open growth
plates in their wrists should not use dowel grips . 7
During practice, they should alternate between
swinging and weight-bearing even ts Y They should
learn and practice correct falling and landing
techniques. 9 The presence of trained, knowledgeable,
experienced spotters and the proper use of afe ty
equipment (such as mats and spotting belts) are highly
recommended. 11 It is also important that exposur is
limited to less than 15 hour per week, and that
gymnasts do not participate when in pain Y Finally,
rapid diagnosis and treatment of both chronic and acute
injuries is essential. 5
CONCLUSIO
Inflammation, disruption of normal processes of
growth, and degenerative changes in bone reflect that
the bodies of competitive gymnasts are being physically
stressed beyond their tolerance level. Damage to the
epiphyseal plate i common in gymnasts, and while
early d iagno is and conservative treatment of the injury
has a good progno is for recovery, if left untreated the
injury may have erious, life-long effect . Steps mu t be
taken to prevent epiphyseal plate injuries in young
athletes. These steps include education of coaches,
parents, and gymnast, a safe training environment, and
limiting exposure to weight-bearing by the upper
extremities.
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Neuropsychology
Syndrome

of

Turner's
by Tulin Cit, Meds 2000

n 1938, a syndrome was identified in which there was
sexual immaturity, small stature, and skeletal
abnormalities due to a full or partial deletion of the X
chromosome in somatic cells'. One of the most w idely
studied aspects of thi disorder is its associated
neurocognitional and behavioural differences. Many
competing theories have been propo ed to account for the
specific neuroanatomical areas in which there are
anomalies, as well as the bases for the production of such
impairments in brain, behaviour, and ability.

I

EUROCOGNITION AL DIFFERENCES

In developmental neuropsychological deficits, uch
as those produced by Turner's syndrome, there is no
contrast between a previous state and the pre ent one.
Only the final result of the deficit and the individual's
attempt to compensate are exhibited. Thus, psychology
ha been slow to accept and identify such ca es 2 •
Turner' patients most predominantly displa y five
major cognitional differences, as compared to nor mal
subjects.

PERFORMANCE VS. VERBAL IQS

The Wechsler IQ scale are used as a measure of basic
cognitive function . These tests have a distinct advantage:
they provide eparate score for verbal and performance
subtests, as well as overall IQ. 3 Previous
neuropsychological studies of patients diagno s ed
clinically and cytogenetically as Turner's syndrome have
indicated that Wechsler performance IQs in the disorder
ranged significantly lower than the verbal IQs (Figure 1
illustrates the IQ results found in Temple and Carney's
tudy '). Other authors 2 ha e also noted that on the
Wechsler Performance IQ te t low scores were over
represented for Turner's girls.
VISUOSP A TIAL ABILITY

Researchers have found that instead of an overall
mental deficiency, which wa often ascribed to Turner's
patients , there are specific non verbal cognitive
impairment that include difficulty with visuospatial
tasks such as perception of left and right a nd
visuomotor drawing• . In normal children, a ex

Figure 1: Mean Verbal , Performance and Full-Scale IQ Scores
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difference is evident between males and females on
both Object Assembly and Block Design subtests of the
Wechsler Intelligence Test for Children (Revised), with
girls performing more poorly than boys '. Results of a
study by Temple and Carney ' suppor ted previous
findings that in Turner's patients, this sex difference
was exaggerated, producing an even greater deficiency
for Turner's girls in those Wechsler subtests.
The basic impairment may be associated with
mental processing and sequencing of rotational shape
transformations in the spatial dimensions of up down,
left right and back front 5 • 6 • In daily activities, this
deficit in rotational transformation is manifested as a
handicap in map reading , drawing floor plans ,
following travel directions, and recognizing facial
expression changes 6 • Ironically, the rotational
transformation disability is not a handicap in learning
to read, and in fact it may be an advantage. Owing to
this impairment, the shapes of letters and words
maintain their meaning by remaining sta tic and
unrotated . Such a cognitive ability specific to Turner's
girls could contribute to an easier process of learning
to read and thus could be an explanation for their high
verbal abilities.
More generally, individuals with Turner 's
syndrome have performed worse on a variety of
visuospatial processing tasks such as spatial reasoning
and extrapersonal space 7, visual memory, mazes,
visual seq uencing and discrimination 8 , and design
copying•.
MEMORY
In one study 5 , Turner 's subjects underwent
neuropsychological testing in order to determine the
hormonal constraints which govern non verbal
memory processes. Results showed that subjects had
memory deficits for non verbal materials within three
perceptual areas: visual, auditory, and tactile . This
type of memory impairment was attributed to an
alteration in the processing of the material to be
remembered. Waber• also found deficiencies in
Turner's patients for the houses and faces components
of the Face Recognition test, illustrating that Turner's
patients have a visual memory deficit for non verbal
materials.
NUMERICAL ABILITY
The Wechsler test has also shown that a relative
difficulty with numbers, a form of dyscalculia, is
associated with the syndrome. Results of Waber 's•
study also supported this finding by showing that
Turner's syndrome subjects scored significantly lower
on overall mathematics achie ement, numerical
reasoning, and geometry and symbols. Analysis of
math processing mechanisms revealed that areas
which involved mathematical concepts seemed to be
compromised to a greater degree than computational
areas. Multiplication was the least affected. The
previous deficiency in rotational transformation also
serves as a handicap in certain mathematical tasks,
especially geometry.
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These defects are predominantly localized to the most
recently de eloped cortical regions. The disturbances
in function are evident in those cognitive processe
associated with the e brain areas, specifically the
posterior right hemi phere.
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MAT URATI O

Waber• propo ed the idea of maturational dela y as
a cause of neurop ychological difference in Turner's
girls. This hypothesi stems from the notion that this
syndrome i a developmental disorder. Thus, it is of
interest to note that the performance of these
individuals qualitatively resemble that of the pre
pubertal child . The e patient exhibit an immature
pattern of performance, and this immaturity translates
into other areas of cognitive and perceptual
functioning as well. For example, the inability to
perceive right and left on another person could reflect
a maturational delay, since these processes trikingly
improve between the ages o f six and ten in normal
subjects.
Empirically, there is also electrophysiological
evidence to upport thi hypothe is. It has been noted'
that adult Turner 's syndrome patients display an
averaged e oked response which is most similar to
that of female children between the ages of six and
nine. Thi finding has been most readily attributed to
the postulated immaturity of the cerebral cortex.
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Mosaicism in Turner' yndrome genotype i a
condition characterized by a combin.ation of normal and
abnormal cell lines. It is suggested that various a pects
of the syndrome's cognitive effects may be less s vere
among those with mosaicism '. Thus, the behavioural
phenotype of Turner's patients with mosaic genotype is
less deviant from the normal pattern than is that of pure
45XO. Mo aicism is found to cause a less dramatic
expression of the syndrome, as occurs in other genetic
disorder .
U D ERLYING CAUSES O F NEUROCOG NITIO AL
AND A ATO M ICAL DIFFEREN CES
Many studies have implicated
various
neuroanatomical areas in which impairments might
result in the pattern of the cognitive deficits described
abo e. However, the underlying mechani m(s) through
which these impairments are produced are still vague.
Three main theories as to the cause of brain,
behavioural, and cognitive differences for those afflicted
with Turner' yndrome are propo ed.
G E ETIC
Individuals with Turner's syndrome, who lack the
genetic material provided by the X chromosome, are
thought to be predisposed to certain cerebral anomalies9 •
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Evidence from laboratory studies indicate that
gonadal hormones play a crucial role in the normal
cerebral matura tion of many mammalian specie 2 • In
applying this hypothesis to human studies, and more
specifically to Turner's patient tudies, it is difficult
to separate the effects of the genetic anomalies cited
previously from the effects of hormonal absence.
However, sex hormones, which are missing as a
result of o arian dysgenesis, may serve as key factors 2 •
A lack of hormone at a critical period of embryonic
development could exert an influence on the evolving
central nervou y terns. Money 2 proposed that this
process of hormonal influence is involved in the neural
mechanisms of territoriality and territorial defence,
which are sex differentiated, being stronger in the
male. A connection between these behaviours and
spatial ability is then made by postulating the existence
of a hormonal mechanism within the period of fetal
development which might consequently affect space
perception as it relate to territorial behaviour.
These three theorie , proposed to attribute causality
of neurocognitional deficits and neuroanatomical
anomalie to specific mechanisms, are not complete by
any means. Each fails to take into account certain
aspects of the condition . one mention the effect of
environmental influence , most likely because Turner's
syndrome is looked at in such a biological and genetic
manner. Rove di cusses the implications of certain
environmental factor , citing a 1987 study by Bender,
Linden, and Robinson which showed that children with
sex chromosome abnormalities (including Turner's)
from poorly functioning families were more impaired in

- - - - - - - --
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their intellectual and psychosocial development than
were those from better functioning families. Thus, when
com paring level of function in Turner' patients, it i
important to consider the specific environmental and
familial background of each girl.
Each of these theories -genetic, maturational dela y,
and hormonal - offers only part of an explanation of the
causal chain. Chromosomal abnormalities can alter
brain development because they can lead to deviations
from normal hormonal levels and sensitivity.
Alterations in hormone exposure, in turn, can lead to
differential brain development which manifests itself as
cognitive and behavioural impairments. In this context,
environmental influences al o ac t to determine th e
ex tent of hormonal effects, and thus the severity of
deficiencies.
Turner's syndrome, like so many o ther biological
and genetic disorders which reveal neurocognitional
alterations, is the result of a dynamic relationship
between genetics, endocrinology, and environment.
Each factor serves to magnify or diminish th e
consequences of this mysterious disorder. Through it
tudy, we may learn to aid those afflicted wi th it, and to
develop a better understanding of the remarkable
functions of the mind and bod y.
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Second-Line
Otitis

Therapy
Media

for

by Richard Levine, Meds '97
here has been a lot of debate regarding the ideal
treatment of acute otitis media (AOM) in children.
Most parties have agreed that amoxicillin is
probably the best first-line therapy. However, until
recently there has been little consensus as to which
treatment is ideal when first-line therapy is not
effective. The efficacy of an antimicrobial is asses ed by
culturing middle ear fluid before and after
administration of a drug. Based on the results of
several studies, the Ontario Antilnfective Review Panel
provided recommendations for management of AOM
(Appendix 1). Recommended first-line therapy is
amoxicillin or pivampicillin. Second-line therapy is
TMP /SMX (trimethoprim/ sulfamethoxazole), ER/SX
(erythromycin/ sulfisoxazole), AM/CL (amoxicillin/
clavulanate), cefixime, cefaclor, or CFXAX (cefuroxime
axetil).

T

Wh a t are the pathogens?
Decisions regarding choice of antimicrobial agent
are partly based on the most likely pathogen. The most
probable organisms in AOM in children are: S.
pneumonia (-35%), H. influenza (-25%), M. catarrhalis
(-15%), Strep. Grou p A, S. a u reus, Gram-negative rods,
anaerobes or viruses. 1

Why am oxicillin for fi rst-line management?
The goal of therapy is to targe t the most likely
organism. More than 90% of AOM in healthy children
will resolve with amoxicillin. 2 In addition, amoxicillin
has a reasonable cost, acceptable flavour and a
relatively low rate of adverse effects.

Wh y do sy mptoms persist?
Prior to ini tiating second-line therapy, reasons for
symptom persistance should be considered. Po ible
reasons include concurrent viral infection, bacterial
resis tance to firs t-line therapy, failure to erad icate
sensitive bacteria, middle ear effusion, poor host
defences or non compliance. This last factor may be due
to physician errors (no t explaining side effects),
pharmacist errors (incorrect labeling) or parental
factors (drug cost).

Wh y is second-line therap y used?
There are two major reasons for initiating secondline therapy. In some situations, incomplete treatment
of AOM may have undesirable consequences (e.g .
mas toidi t is or meningitis). Chi ldren wi t h severe
symptoms, who are young and febrile or
immunocompromi ed are especially prone to this.
Secondly, an episode of AOM might involve
organisms tha t are resis tant t o first- line t h erapy.
Children whose ymptoms persist beyond 48-72 hour ,
who have a new AOM during first-line or prophylactic
therapy, or who have had an AOM unresponsiv to
amoxicillin within t he pas t 2 months may harbour
resistant organisms. 3
Strains of H. influenza, M. catarr h alis (and S.
aureus) are resistant to fir t-line therapy because they
produce ~lac tamase (an enzyme), w h ich h ydrolyzes
many of the penicillins . In vitro, up t o 40 % of H.
influenzae, and 90 % of M. catarrhalis produce
~lac tamase. • Up to 16% of treatment fail u res are d ue to
~lactamase production.' Effective second-line therapy
includes AM/CL (CL=cla ulanic acid is a ~lactama e
inhibitor), ER/SX (erythromycin alone is ineffective),
orTMP/SMX.
Some strains of S. pneumonia display a n tibiotic
resistance. In vitro, up to 40% of Pneumococci were
resistant to TMP /SMX. 6 In addition, S. pneumonia
may acquire resis tance to penici ll ins, secondary to
changes in penicillin binding proteins. AM/CL would
be an effective second-line therapy. S. pneumonia are
infrequently resistant to erythromycin, or
cephalosporins. 7
CEPHALOSPORINS ARE EFFECTIVE AGAINST
MOST GRAM NEGATIVE BACILLI
SIDE EFFECTS
Every dru g used to treat AOM has the potential to
cause side effects (mo t commonly GI upset and rashes).
Amoxicillin causes the fewe t side effects. However, the
addition of Clavulinic acid increases the occurrence of
diarrhoea . ausea, vomiting and gastritis are relatively
common with erythromycin. Sulpha dr u gs are rarely
associated wi th Stevens-John on syndrome and bone
marrow suppression. 7
DOSAGE
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Some of the cephalosporins and TMP /SMX have the
advantage of twice daily dosing, compared to dosing
three times a day common to many of the second-line
therapies.
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0

Dose

Cost per day

($/ kg)
First-Line

Second-Line

Arnoxicillin
Pivampicillin

40 mg / kJ / d , dividedj h
4060 mg kg / d , divid ql2h

0.070.11

TMP/ SMX
(T rimethoprirn I SuI famethoxazole)
ER/SX (Erythrom~/Sulfisoxazole)
AM / CL (Amoxic· · / Ciavulanate)
Cefixime
Cefaclor

812 mg / kg / d, divided q12h
40 mg / kg / d, divided q68h
40 mg / kg / d, divided q8h
8 mg/kg/d, divided q1224h
40 mg / kg / d, divided q812h
40 mg/kg/d , divided q12h

0.020.03
0.10
0.15
0.130.23
0.17

0.01
0.09

O.o3

CFXAX (Cefuroxime axetil)
Third-Line

T rimethoprirn
Clarithromycin

not in children <12 years old
15 mg / kg / d, divided q12h

Prophylaxis

TMP/SMX
Amoxicillin
Piva mpicillin

half the usual
therabutic
dose id

THE CEPHALOSPORI S
Despite being one of the better tasting preparations,
cephalosporins are relatively expensive. In addition ,
Cefaclor is less effective than orne other antibiotics, and
Cefixime is not very effective again t Pneumococci.
Cefixime is very useful while travelling, because it does
not require refrigeration. 8
MANAGEMENT PLAN
Once the diagnosis of AOM is made, first-line therapy
(amoxicillin or pivampicillin) is initiated for 7-10 days. If the
patient is allergic to penicillin than a uitable econd-line
therapy can be initia ted (ER/SX, TMP /SMX). If after 7-10
days symptoms have subsided, then treabnent is complete.
If symptoms fail to improve within 48-72 hours, then
bacterial resistance is likely, and a witch to a suitable
second-line therapy is indicated . AM/CL, or ER / SX,
TMP / SMX could be used against f3lactamase producing
strains. Of the e, TMP /SMX is the least expensi ve,
cephalosporins are the most expensive. However, if
penicillin resistant S. pneumonia is uspected then
TMP / SMX may not be effective. If, at 48-72 hours, the child
is toxic or experiencing complications then myringotomy
and or tympanocentesis (with culture and ensitivity to
identify the pathogen) should be considered.
Relap e (reinfection with the same organism) within 4
days of discontinuing therapy should be treated as failure to
respond to therapy. However, recurrence (infection with a
new organism) 5 to 14 days after di continuing therapy
should be treated with first-line antibiotics.
Persistence of effusion, or tympanic membrane
inflammation (despite resolution of otalgia) after 10-14 day
can be managed by continuing the same therapy for 14 to 21
days in total. Alternatively, the patient can be observed
without antibiotics. Persistence i often viral in origin, but
predisposes to bacterial infection.
1hree or more infections in 6 months or 4 infections per
year without chronic effusions between episodes is treated
acutely as failure to respond . Thi is followed by
c hemoprophylaxis and or tympanostomy and
m y ringotom y.• C&S res u lts are u ed to guide further
management.

CONCLUSION
Despite increasing resistance to antimicrobial therapy,
most children with acute otitis media should respond to
amoxicillin within 48-72 hours. If this is not the case then
infection with resistantS. pneumonia, H. influenza or M.
catarrhalis should be suspected. Second-line therapy with
TMP / SMX ER/SX or AM / CL can be initiated depending
on the suspected pathogen . Cephalosporins are an
expen ive alternative. If there is persistent or recurrent
fever or otalgia then tympanocentesis or myringotomy can
be used to guide antimicrobial therapy.
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A CASE OF " A FRIGHTENING
EXPERIENCE IN THE MIDDLE OF
THE NIGHT"
by Paul Collins, Meds '99

2-year-old male child is brought by his mother to
the Emergency Department at 0400h. The mother
describes an episode during which the child
stopped breathing, turned red, and wa gagging. She was
afraid he might die.

A

PLEASE STOP A
QUESTIO S:

D A SWER THE FOLLOW! G

1.

arne the condition.

2.

Define the condition.

3.

What is your differential diagnosi ?

On examination, the child has a temperature of 37.5,
BP 95/60, and HR 75. He is slightly cyanosed. Head and
neck examination normal. o signs of airway ob truction.
Chest exam normal. eurological exam unremarkable.
PLEASE STOP A
QUESTIO S:

D A SWER THE FOLLOW! G

4.

What are normal BP and HR for a 2-year-old?

5.

Explain the bradycardia.

6.

Explain the cyanosis.

The child is admitted to ho pital, a complete workup
is ordered and he is monitored for several nights. Pain is
never observed by hospital taff. ASSUME that, despite
exhausting all available diagno tic means, no pathological
explanation for the initial pain wa found.
PLEASE STOP AND THINK ABOUT THIS QUESTIO

London Regional Cancer Centre

The UNIVERSITY of WESTERN ONTARIO
Faculty of Medicine • Department of Oncology
790 Commi ioner Road Ea t,
London , Ontario 6A 4L6
(519) 685-8600

Dr. Vivien Bram well, MB, B , PhD, FRCPC
Interim Chief Executive Officer
London Regional Cancer Centre
Professor and Acting Chair
Department of Oncology
The London Regional Cancer Centre i a modem,
well-eguipped, ambulatory treatment facility.
The opportunity ex i t to participate in clinical
and ba ic research program .

7.

What do you do now?

The mother is a 26-year-old unemployed single
parent. Her parents put her up for adoption when he
was 5 years old, and she has not been in contact with
them since. She lives alone because her husband left a
year ago and is seeking a divorce. They had one other
child that died of SIDS. She feels depre sed and lonely. In
the past year her son has been admitted to hospital for
multiple problems including failure to thrive, lethargy
and recurrent diarrhoea. Throughout the interview he
insists that she is a "good parent" and that she "loves her
son". She also comments that she "doesn't know what
she'd do without the doctor's help". A psychiatric consult
is ordered.
PLEASE STOP A
QUESTIO S:

D A SWER THE FOLLOW!

G

The Department of Oncology offer postgraduate training
in Medical and Radiation Oncology.

8.

What rare p ychiatric di order does this cenario
suggest?

For details, contact:
Dr. Walter Kocha, MD, FRCPC
Re idency Program Director
Department of Medical Oncology
(519) 685-8638

9.

De cribe the condition.

Dr. Jim Gilchri t, MB , FRCPC
Re idency Program Director
Department of Radiation Oncology
(519) 685-8650
The Ontario Cancer Treatment and Re earch Foundation

42

10. How could pain, failure to thrive, lethargy, and
diarrhoea be exogenously induced?
11. What is the role of the physician in this situation?
12. Discuss principles of intervention.
The mother is currently under psychiatric care and
the child will reside in a foster-home indefinitely until her
recovery.
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ANSWERS TO CASE STUDY

disorders such as apnoea or an ALTE, non-medical causes
must be considered. Obtain a detailed psychosocial history
of the mother.

1. Apparent Life-Threatening Event (ALTE).
2. An episode characterized by apnoea (central or
obstructive), change in colour (usually cyanosis or pallor,
occasionally erythema or plethora), change in muscle tone
(limpness or stiffness), and choking or gagging. The episode
is frightening to the observer. In some cases the observer
fears that the infant has died. Previously used terms include
"aborted crib death" or "near-miss SIDS".

8. Munchausen Syndrome by Proxy (MSP).
9. MSP is a recently described rare form of child abuse
in which a caregiver (almost always the mother) fabricates
or induces symptoms in a child in order to attract medical
attention. The condition is unders tood in terms of the
mother's need for a relationship with a physician that is
rooted in a profound sense of early abandonment. The
infant in this sadoma ochistic interaction is dehumanized
and is used as a fetishistic object to control the relationship.
MSP is a serious form of child abuse that may remain
undetected for years. Victims suffer serious physical and
psychological damage and sometimes even death.

3. Common causes of ALTE (from Most to Least
Common) include: Gastroe ophageal Reflux (GER);
eurologic (seizure disorder); Infectious (meningitis);
Re piratory [respiratory syncytial virus (RSV), pertussis,
pneumonia, congenital central hypoventilation syndrome
(CCHS)], Airway Abnormality or Obstruction; Vasovagal
Syndrome; Cardiac (Wolff-Parkinson-White syndrome,
arrhythmia), Metabolic-Endocrinologic; Munchausen
syndrome by proxy.
4.

Solving

10. Apnoea (smothering), failure to thrive (starvation),
lethargy {dehydration, malnutrition), diarrhoea (laxatives).
11. Physicians must be aware that MSP exists, can
present in the form of anything, and should be considered
as a diagnosis in ca es that do not make medical sense.
MSP is a severe form of child abuse and must be reported
to local Child Protection Service when the child is
endangered. Physicians play a key role in identifying these
children and recommending the best course of action to the
rest of the system.

ormal BP 90/60 & HR 110 in the 1-2 year age group.

5. Bradycardia is defined as abnormally slow heart rate.
The combination of repeated episodes of apnoea and
hypoxia eventually slows the heart ra te, an effect mediated
by the vagus nerve.
6. Cyanosis is defined as blue, grey, or purple
discoloration of the skin due to reduced haemoglobin in the
blood. Caused by hypoxia and hypercapnia secondary to any
condition interfering with air entry into the respiratory tract.

12. After the condition is confirmed, a multidisciplinary
team aims to protect the abused child and change the
pathological parent-child relationship. Comorbid psychiatric
conditions in the illness perpetrators and psychological
manifestations in the children must be addressed.

7. Whenever comprehensive physical examination and
investigations fail to reveal the aetiology of childhood
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LIGHTNING

STRIKES

FOUR

TIMES

by Dr Victoria Mok Siu , MD, FRCP, FCCMG

Y

ou have a new patient, an 18-year-old woman, who
has recently married and wishes to begin family
planning. She has a history of Tetralogy of Fallot
with surgery having been performed in early childhood.
She wants to know if she is at risk of having a child with a
congenital heart defect and what can be done to increase
her chances of having a healthy child.
1. What further information is necessary before you can
answer her questions? She has been relatively healthy
and does not drink or smoke. She is on no medications.
Although she has had intermittent complaints of
dyspnoea and chest pain, a recent treadmill exercise
ECG showed excellent endurance to physical effort. She
is followed annually by her cardiologist who feels there
is no contraindication to pregnancy. Her family history
is negative for any individuals with congenital heart
defect or other congenital malformations.
2. What is her risk of having a child with:
(a) congenital heart defect?
(b) neural tube defect?
(c) Trisomy 21?

Your patient becomes pregnant for the third time. A
routine ultrasound detects only one kidney but fetal
echocardiogram is normal. She delivers a healthy 6 lb. 2 oz
boy. As a precaution, you refer him for a cardiology
assessment and he is found to have a small ventricular
septal defect. His maternal grandmother now comes to see
you and insists there must be a reason for all of the heart
defects in this family. You start to reassess the situation.
ow that you think of it, there do seem to be more than
just heart problems.
The child with the PDA has been slow to talk and it is
difficult to understand his speech. His mother states that she
herself required speech therapy throughout school and her
speech is still quite hypemasal. She describes herself as a
"slow learner". The baby with the VSD and unilateral renal
agenesis tend to regurgitate frequently through his nose.
6. What type of problem is suggested by these symptoms?

On looking do ely at the mother and two children,
you note that they share some physical characteristics.
They are not strikingly dysmorphic but they do have small
ears and hypertelorism (increa ed distance between the
pupils). Mother has a long nose and high nasal bridge.

3. What general and specific recommendations would you
have regarding management of a pregnancy?
A year later, she returns, two months pregnant, having
been on folic acid supplements. Fetal echocardiogram at
18 weeks demonstrates the presence of hypoplastic left
heart syndrome. She and her husband are coun elled
regarding the extremely poor prognosis for their baby and
they elect to continue the pregnancy. Their daughter is
born at term weighing 5 pounds and dies at 3 days of age.
4. Has her recurrence risk for congenital heart defect
changed in view of thi history?

Two years later, she is again pregnant and you follow
the previous plan of management. This time the fetal
echocardiogram reveals an apparently normal fetal heart.
She gives birth at term to a 6 lb. 4 oz son. At his 1 month
checkup, you detect a heart murmur. The child is found to
have a patent ductus arteriosus (PDA). The parents are
rea sured that this is a minor congenital heart defect but he
requires surgical repair.

5. Are you becoming suspicious that there may be some
underlying genetic disorder or is this mother just
unlucky?
ABOUT THE AUTHOR

Dr Victoria Mok Siu is a medical geneticist and
paediatrician at the Regional Medical Genetics Centre and
CPRI (Child and Parent Resource Institute) in London. She is
an assistant professor in the Faculty of Medicine.
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7.

What is your diagnosis?

8.

What tests will you order to confirm this diagnosis?

9.

ow that you have a definite diagnosis, what is the
recurrence risk?

10. Does this alter your plan of management for future
pregnancies?
11. Your patient's sister is now pregnant and very worried
about her risk of having a child with congenital heart
defect. What can you tell her?
12. Is this just another one of those esoteric cases that
you'll never see in practice?

- - - - - - - - - - - - - - - - - - - - - - - - U. W.O. Medica/Journal 66 (1) 1996

·---

__e_m~ica
~tm_
p_
act~a
-n
~~
c~a
-s_o
_n
~er po
~ y. ----the better. That' why it make en e to pre cribe
TRI-CYCLEN* (with norgestimate and ethinyl
e tradiol). An OC with low hormonal impact.
TRI-CYCLEN contains the low activity selective
progestin norgestimate, in a phased low dose
for low overall hormonal impact. 2
Plu , TRI-CYCLEN i more than 99% effective.
o whether they' re new tarts or re tarts,
mo t women who start on TRI-CYCLE. stay
on TRI-CYCLEN.

-----------~------------~e~
es
_s_c

An OC with

low hormonal impact
that blends with
nature's cycle.

t

f'Qr lndrx ol 0.

"TFlkknwl: 0 I•

-

·Ortho Inc • 1996

orgeshma ettunyt eslr.ldiol

Cyclen·
Effective low impact
contraception

P r ob l em

So lvi ng
be a sociated with a deletion of part of the long
arm of chromo orne 22. Other congenital
malformation syndromes which may have the
same 22q11.2 deletion include DiGeorge
syndrome and CHARGE association. All of the e
di orders are now grouped under the acronym of
CATCH 22 which describes the various systems
that may be affected, i.e. Cardiac, Abnormal
facies, Thymic hypopla ia, Cleft palate ,
Hypocalcemia (due to hypoparathyroidism).
Affected structures are all derivatives of the third
and fourth pharyngeal pouches. There is
con iderable intrafamilial variation (as
demonstrated by this case his tory) as well as
interfamilial variation. In the mo t evere cases, a
newborn may present with hypocalcemic eizures,
recurrent infection due to decreased T cell
function, and major congenital heart defect. Much
milder ca es may not be diagnosed until a child i
inve tigated for learning problem and speech
delay.

ANSWERS TO CASE STUDY
1.

Family hi tory of congenital heart defects, other
congenital malformation , recurrent miscarriages
or stillbirth
History of making/ alcohol intake
Exercise tolerance, recent cardiac evaluation

2.

(a) In general, the risk of having a child with
congenital heart defect if one parent is affected is
approximately 1 in 30 (3%).
(b) Based on her negative family history, her risk
of having a child with neural tube defect is the
arne a
that of the general population,
approximately 1 in 800.
(c) Her risk of having a child with Tri omy 21
depends on her age at delivery. At a maternal age
of 20 year , the risk is about 1 in 1650.

3.

GE ERAL:

(i)

periconceptional folic acid upplements at a daily
dose of 1 mg PO to decrea e the ri k for neural
tube defect.

8.

Occa ionally, the deletion may be detected on
routine chromosome karyotyping, especially if
you indicate that you are interested in the 22q
region. However, in the majority of cases, pecial
reque t mu t be made for a FISH (Fluorescence InSitu Hybridization) tudy, again specifying the
22q region. The cytogenetics laboratory will
prepare a metaphase chromosome spread,
hybridize to a 22q11.2 D A probe, and utilize a
fluorescent marker to determine whe ther or not
there i a deletion ( ee illustra tion).

9.

In this family, the mother was proven to ha ve a
22q11.2 deletion which occurred de novo (neither
of her parents had the deletion). Both of her sons
(and likely her daughter) inherited the deletion . In
any future pregnancy, she will have a 50% ri k of
passing on the deletion. Similarly, her affected
children will have a 50% risk of passing on the
deletion to their offspring.

(ii) maternal serum screening at 15 1 / 2 weeks to
screen for risk of neural tube defect and Down
yndrome.
SPECIFIC:
(iii) fetal echocardiogram at 18 week to screen for
major cardiac malformation .
(iv) careful monitoring of her cardiac status and SBE
prophylaxis for any dental extraction and
potentially eptic surgical procedure .
4.

Yes. With an affected mother and child, the
recurrence risk is definitely increased to at least
10%.

5.

Patent ductus arteriosus is quite common in
premature infants, and usually closes
spontaneously or with the aid of indomethacin .
However, PDA is rare in term infant . You hould
now be con idering very strongly the possibility
of a pecific underlying diagnosis.

6.

7.

46

Velopharyngeal insufficiency. You should look for
evidence of any palatal problems such as a cleft
palate (overt or submucou ) or bifid uvula . On
e amination, mother doe have a ubmucous cleft
palate.
The combination of velopharyngeal insufficiency
with submucous cleft palate, cardiac defect,
learning problems, and facial features section
(long nose with prominent nasal root, ear
anomalie )
i
typical
for
Shprintzen
(velocardiofacial) yndrome, first described in
1978. In 1992, Shprintzen syndrome was found to

10. Chorionic villus sampling at 10 to 12 weeks or
amniocentesis at 15 to 18 weeks could be offered
to determine if the fetus has inherited the deletion
and, if so, fetal echocardiogram would be
indicated to determine the severity of congenital
heart defect.
11. Since this is a de novo dele tion in your patient,
her unaffected sister has the arne risk as that of
the general population for having a child with
congeni t a l heart defect. o special prenatal
inve tigations are indicated for the ister.
12.

o. Deletions of 22q have been found in up to 5%
of all newborns with heart defects and may
represent the mo t common chromo orne
abnormality after Down syndrome (Trisomy 21) .
The spec t rum of problems seen in CATCH 22
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Problem
results in many different specialists having the
opportunity of assessing and diagnosing a patient:
E T, cardiology, pia tic urgery, endocrinology,
neurology, immunology . Undoubtedly, there are
many undiagnosed cases, particularly as thi s
deletion yndrome is just starting to be
recognized.
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Vocabulary
Jordan Solmon, Meds '98

he Vocabulary Section of this issue was compiled
with the help of health care providers in the area of
paediatric medicine from seven different countries.
The forum for this exchange of ideas was an Internet chat
channel called International Pediatric Chat. The website
for this organization can be found at the following URL:
http/ /: www.pedschat.com. Instructions on how to
access the chat channel are provided at that site. Below is
an excerpt from this innovative new service.

T

"International Pediatric Chat (IPC) is an organization
of pediatric professionals who use live Internet typing,
voice chat, and hopefully someday video conferencing as
a means of communicating with each other. It was started
May 16, 1996 by Dr Julius Edlavitch from Minneapolis,
Minnesota. It is like a giant doctors' lounge where
pediatricians, pediatric nurse practitioners, pediatric
specialists, pediatric nurses, and other medical
professionals interested in children meet. Below are some
of the benefits and features section of IPC.
live socialization of the members on a regular
basis to develop professional friendships never before
possible
professionals can drop into this lounge on a 24
hour a day basis, 7 days a week, to share medical and
personal information
medical education sessions with international
perspectives promote free thinking and help
professionals approach some of their dilemmas with new
and culturally diverse perspectives
need help? 24 hours 7 days a week, pediatric
professionals can get live help from others; one can share
cases like never before".

3.

NIPPLE CONFUSION

a.
b.

a.k.a. Triple nipple disease
infant thinks his/her nostrils are nipples
infant is born with extra nipples
infant refuses mother's nipple after experiencing
bottle

c.

d.
4.

a.
b.

hernia of rectus muscle
an unusual constitutional susceptibility to a
particular disease
c. anomaly resulting in Tethered Cord Syndrome
d . the rest period of the cardiac cycle of a neonate,
prior to systolic muscle contraction
5.

SYNOPHYRS

a. converging brain cells
b . secondary sensations accompanying actual
perceptions
c. congenital fusion of the testes into one mass
d . eyebrows that meet in the midline
6.

HURLER DISEASE

overuse syndrome typified by synovitis of biceps
brachialis muscle
b. congenital lysosomal storage disease
c. a.k.a. congenital pyloric stenosis
d . plague to hit Blue Jay pitchers in 1994 season
a.

7.

MONGOLIAN SPOTS

PAEDIATRIC MEDICAL VOCABULARY

a.
b.
c.
d.

dermatitis associated with Mongolism (Trisomy 21)
certain bars and restaurants found on Richmond St.
transient blue/black pigmented macules
neonatal red raised lesion

1.

LANUGO

8.

TRICHOTILLOMANIA

a.
b.
c.
d.

fetal hair
an endemic granulomatous disease
a bundle of fibers in the immature CNS
ubiquitous colour of neonates' eyes

a.
b.
c.
d.

compulsive mischievous behaviour
affective disorder triggered by Trichomonas
compulsive pulling out of one's hair
meaningless repetition of words and phrases

9.

TALIPES EQUINOVARUS

2.

PRUNE-BELLY DISEASE

a.
b.
c.
d.

diarrhea
congenital truncal maroon discoloration
Eagle Barrett Syndrome
eponym for appearance of baby's skin after
prolonged immersion in bath water

a.
b.
c.
d.

flatfoot
clubfoot
fear of horses
congenital lesion at level of cauda equina

10. ELEKTRA COMPLEX
a.

ABOUT TilE AUTilOR
Jordan B. Solman is a third-year medical student with a
BSc from the University of Toronto. He is interested in
paediatric surgen;.
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DIASTEMATOMYELIA

b.
c.

d.

Pseudo-Freudian condition of morbid daughterfather attachment
intendo-caused thumb synovitis
side effect in some paediatric electroconvulsive
therapy recipients
complex of eschar and gangrenous tissue after an
electric bum
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ACTION AND CUNICAL PHARMACOLOGY
NORVASC (amlodipine besyfate) is a calcium ion influx inhibitor (calcium entry blocker or calcium ion antagonist).
Amlodipine is a member of the dihydropyridine class of calcium antagonists.
INDICATIONS AND CUNICAL USE

Hypertension
NORVASC (amlodipine besyfate) is indicated in the treatment of mild to moderate essential hypertension.
NORVASC should normalty be used in those patients in whom treatment with diuretics or beta -blockers was found
ineffective or has been associated with unacceptable adverse effects. NORVASC can be tried as an initial agent in
those patients in whom the use of diuretics and/or beta-blockers is contraindicated or in patients with medical
conditions in which these drugs frequently cause serious adverse effects. Combination of NORVASC with a
diuretic, a beta-blocking agent. or an angiotensin converting enzyme inhibd.or has been found to be compatible and
showed additive antihypertensive effect
Chronic Stable Angina
NORVASC is indicated for the management of chronic stable angina (effort-associated anginal in patients who
remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those
agents. NORVASC may be tried in combination with beta-blockers in chronic stable angina in patients with normal
ventricular function. When such concomitant therapy is introduced, care must be taken to monitor blood pressure
closely since hypotension can occur from the combined effects of the drugs.
CONTRAINDICATIONS
NORVASC (amlodipine besylatel is contraindicated in patients with hypersensitivity to the drug or other
dihydropyridines and in patients with severe hypotension (less than 90 mmHg systolic).
WARNINGS
Use in Patients with Congestive Heart Failure
Safety and efficacy of NORVASC {amlodipine besyiate) in patients with heart failure has not been established.
Caution should therefore, be exercised when using NORVASC in patients with compromised ventricular function,
particularly in combination with a beta-blocker. In a controlled clinical trial using a small number of patients
(58 Norvasc and 60 Placebo) with well compensated congestive heart failure (NYHA Class 11-111), addition of
NORVASC to digoxin and diuretic therapy with or without angiotensin converting enzyme inhibitors did not lead to
worsening of heart failure in the majority of patients treated .
Increased Ang ina and/or Myocardial Infarction
Rarely, patients, particularly those with severe obstructive coronary artery disease, have developed
documented increased frequency, duration and/or severity of angina or acute myocardial infarction on starting
calcium channel blocker therapy or at the time of dosage increase. The mechanism of this effect has not
been elucidated.
Outflow Obstruction {Aortic Stenosis)
NORVASC should be used with caution in a presence of fixed left ventricular outflow obstruction
(aortic stenosis).
Use in Patients with Impaired Hepatic Function
There are no adequate studies in patients with liver dysfunction and dosage recommendations have not been
established. In a small number of patients with mild to moderate hepatic impairment given single dose of 5 mg,
amJodipine hatf-life has been prolonged. NORVASC should, therefore, be administered with caution in these
patients and careful monitoring should be performed. A lower starting dose may be required (see DOSAGE AND
ADMINISTRATION !.
Beta-bloclc:er Withdrawal
NORVASC gives no protection against the dangers of abrupt beta-blocker withdrawal and such withdrawal should
be done by the gradual reduction of the dose of beta-blocker.
PRECAUTIONS
Hypotension
NORVASC (amfodipine besylate) may occasionally precipitate symptomatic hypotension. Careful monitoring of
blood pressure is recommended, especially in patients wrth a history of cerebrovascular insufficiency, and those
taking medications known to lower blood pressure.
Peripheral Edema
Mild to moderate peripheral edema was the most common adverse event in the clinical trials (see ADVERSE
REACTIONS). The incidence of peripheral edema was dose-dependent and ranged in frequency from 3.0 to 10.8%
in 5 to 10 mg dose range . Care should be taken to differentiate this peripheral edema from the effects of increasing
left ventricular dysfunction.
Use in Pregnancy
Although amlodipine was not teratogenic in the rat and rabbit some dihydropyridine compounds have been found
to be teratogenic in animals. In rats, amlodipine has been shown to prolong both the gestation period and the
duration of labor. There is no clinical experience with NORVASC in pregnant women. NORVASC should be used
during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.
Nursing Mothers
It is not known whether amlodipine is excreted in human milk. Since amlodipine safety in newborns has not been
established, NORVASC should not be given to nursing mothers.
Use in Children
The use of NORVASC is not recommended in children since safety and efficacy have not been established in
that population.
Use in Elderly
In elderty patients (~5 years) clearance of amlodipine is decreased with a resuh.ing increase in AUC. In clinical
trials the incidence of adverse reactions in elderly patients was approximately 6% higher than that of younger
population (<65 years). Adverse reactions include edema, muscle cramps and dizziness. NORVASC should be used
cautiously in elderly patients. Dosage adjustment is advisable (see DOSAGE AND ADMINISTRATION!.
Drug Interactions
Beta-blockers: When beta -adrenergic receptor blocking drugs are administered concomit.antty with NORVASC,
patients should be carefully monitored since blood pressure lowering effect of beta-blockers may be augmented by
amlodipine's reduction in peripheral vascular resistance.
Digoxin. Cimetidine, Warfarin: Ptlarmacokinetic interaction studies in healthy volunteers have indicated:
• amlod ipine did not change serum digoxin levels or digoxin renal clearance.
• cimetidine did not after the pharmacokinetics of amlodipine.
• amlodipine did not change warfarin induced prothrombin response time.
ADVERSE REACTIONS
NORVASC (amlodipine besytate) has been administered to 1.714 patients (805 hypertensive and 909 angina
patients) in controlled clinical tria ls (vs placebo alone and with active comparative agents). Most adverse
reactions reported during therapy were of mild to moderate severity.
Hypertension
~n the 805 hyp~rtensive patients treated with NORVASC in controlled clinical trials, adverse effects were reported
10 29.9% of patients and required discontinuation of therapy due to side effects in 1.9% of patients. The most
common adverse reactions in controlled clinical trials were: edema (8.9%), and headache {8.3%).
The following adverse reactions were reported with an incidence of ~. 5% in the controlled clinical trials
program (n=805j:
Cardiovascular. edema (8.9%1. palpitations (2-0%1, tachycardia (0.7%1. postural dizziness (0.5%1. Skin and
Appendages: pruritus (0.7%). Musculoskeletal: muscle cramps (0.5%). Central and Peripheral Nervous

System: headache (8.3%), dizziness (3.0%). paresthesia (0.5%1. Autonomic Nervous System: Hushing (3.1%1.
increased sweating (0.9%1, dry mouth (0.7%1. Psychiatric: somnolence (1.4%1. Gastrointestinal: nausea (2.4%1.
abdominal pain (1.1%1. dyspepsia (0.6%1. constipation (0.5%1. General: fatigue (4.1%), pain (0.5%1.
Angina
In the controlled clinical trials in 909 angina patients treated with NORVASC. adverse effects were reported in
30.5% of patients and required discontinuation of therapy due to side effects in 0.6% of patients. The most
common adverse reactions reported in controned clinical trials were: edema (9.9%} and headache (7.8%).
The following adverse reactions occurred at an incidence of ~.5% in the controlled clinical trials program
(n=9091:
Cardiovascular. edema (9.9%1. palpitations (2.11%), postural dizziness (0.6%1. Skin and Appendages: rash (1 .0%1.
pruntus (0.8%). Musculoskeletal: muscle cramps (1 .0%). Central and Peripheral Nervous System: headache
17.8%1. dizziness (4.5%1. paresthesiall .ll'41. hypoesthesia (0.9'!11. Autonomic Nervous System: fiushing (1.9%1.
Psychiatric: somnolence (1 .2%), insomnia {0.9%1. nervousness (0.7%1. Gastrointestinal: nausea (4.2%),
abdominal pain (2.2%1. dyspepsia (1 .4%1. diarrhea (1 .1%1. flatulence (1 .0%1, constipation (0.9%). Respiratory
System: dyspnea (1.1%1. Special Senses: abnormal vision (1 .3%1. tinnitus (0.6%1. General: fatigue (4.8%1.
pain (1.0%1, asthenia (1 .0%1.
NORVASC has been evaluated for safety in about 11 ,000 patients with hypertension and angina.
The foii<Ming events occurred in <1% but >0.1% of patients in comparative clinical trials (double-blind
comparative vs placebo or active agents; n = 2.615) or under conditions of open trials or marketing experience
where a causal relationship is uncertain.
Cardiovascular: arrhythmia (including ventricular tachycardia and atrial fibrilation), bradyca rdia, hypotension,
peripheral ischemia, syncope, tachycardia, postural diuiness, postural hypotension. Central and Peripheral
Nervous System: hypoesthesia, tremor, vertigo. Gastrointestinal: anorexia, constipation, dysphagia, vomiting,
gingival hyperplasia. General: asthenia ', back pain, hot flushes, malaise, rigors, weight gain. Musculoskeletal
System: arthralgia, arthrosis, myalgia. Psychiatric: sexual dysfunction {male' and female), insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization. Respiratory System: epistaxis. Skin and
Appendages: pruritus', rash erythematous, rash maculopapular. Special Senses: conjunctivitis, diplopia, eye
pain, tinnitus. Urinary System: micturition frequency, micturition disorder, nocturia. Autonomic Nervous System:
dry mouth, sweating increased. Metabolic and Nutritional: thirst Hemopoietic: purpura.
tThese events occurred in less than 1% in placebo controlled trials, but the incidence of these side effects was
between 1% and 2% in all multiple dose studies.
The following events occurred in g).1% of patients: cardiac failure, skin discoloration, urticaria, skin dryness,
alopecia, twitching, ataxia, hypertonia, migraine, apathy, amnesia, gastritis, increased appetite, coughing,
rhinitis, parosmia, taste perversion, and xerophthalmia.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Symptoms
Overdosage can cause excessive peripheral vasodilation with marked and probably prolonged hypotension and
possibly a reflex tachycardia. In humans, experience with overdosage of NORVASC (amlodipine besylate) is limited.
When amlodipine was ingested at doses of 105-250 mg some patients remained normotensive with or without
gastric lavage while another patient experienced hypotension (90150 mmHg) which normalized following plasma
expansion. A patient who took 70 mg of amlodipine with benzodiazepine developed shock which was refractory
to treatment and died. In a 19 month old child who ingested 30 mg of amlodipine (about 2 mglkg) there was no
evidence of hyl)<ltension but tachycardia (180 bpm) was observed. Ipecac was administered 3.5 hrs after ingestion
and on subsequent observation tovemight) no sequelae were noted.
Treatment
Clinically significant hypotension due to overdosage requires active cardiovascular support including frequent
monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume
and urine output A vasoconstrictor (such as norepinephrine) may be helpful in restoring vascular tone and
blood pressure, provided that there is no contraindication to its use. As NORVASC is highly protein bound,
hemodialysis is not likely to be of benefrt Intravenous calcium gluconate may be beneficial in reversing the
effects of calcium channel blockade. Clearance of amlodipine is prolonged in elderly patients and in patients
with impaired lfver function. Since amlodipine absorption is stow, gastric lavage may be worthwhile in some cases.
DOSAGE AND ADMINISTRATION
Dosage should be individualized depending on patient's tolerance and responsiveness. For both hypertension
and angina, the recommended initial dose of NORVASC (amlodipine besyfate) is 5 mg once daily. If necessary,
dose can be increased after 1-2 weeks to a maximum dose of 10 mg once daily.
Use in the Elderly or in Patients with Impaired Renal Function
The recommended initial dose in patients over 65 years of age or patients with impaired renal function is 5 mg
once daily. If required, increasing in the dose should be done gradually and with caution {see PRECAUTIONS).
Use in Patients with Impaired Hepatic Function
Oosage requirements have not been established in patients with impaired hepatic function. When NORVASC is
used in these patients, the dosage should be carefully and gradually adjusted depending on patient's tolerance
and response. A lower starting dose of 2.5 mg once daily should be considered (see WARNINGS).
DOSAGE FORMS
Ava ilability
NORVASC is available as white octagonal tablets containing amlodipine besylate equivalent to 2.5, 5 and 10 mg
amlodipine per tablet The respective tablet strengths are de bossed on one tablet face as .. NRV 2.5.. , .. NRV 5·
and " NRV 10" with " Pfizer· on the opposite face. The 5 mg tablet is scored. Supplied in white plastic (high density
polyethylene) bottles of 100 tablets for each strength. Also the 5 mg and 10 mg are supplied in bottles of 250 tablets.
STORAGE
Store at 15-JO"C. Protect from light
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Problem

Solving

ANSWERS TO PAEDIATRIC
VOCABULARY
1.

a) The fine hair on the body of a fetus.

2.

c) Also known by the eponym Eagle Barrett
Syndrome; congenital anomaly whicn gives the
abdomen a wririkled appearance re embling dried
fruit; consists of bilateral megaureter,
hY.dronephrosis, and may include megabladder,
bilateral cryptorchidism, and/ or mega urethra.

3.

4.

d) Because of different mechanics invol ed in
sucking from a bottle, an infant switched to breast
feeding may refuse to latch onto the mother's nipple.
c) A malformation in which the spinal cord is split by
bone spicules or a fibrous band. This condition and a
lipomatous tumor produce Tethered cord syndrome,
with resultant abnormalities of distal sensation, gait,
and bladder or bowel function.

6.

b) Deficiency of the enzyme alpha-L-Iduronidase is
associated with kyphosis and profound loss of CNS
function. Onset is at about 1 year; the cornea appears
cloudy, and hepatosplenomegaly is present.

7.

c) Mongolian spots are transient dark blue to black

pigmented macules seen over the lower back and
buttock in as many as 90% of black, Indian, and
oriental infants.
8.

c) This is a condition in which one is compelled to
pull out one's hair as a means of relieving the anxiety
caused by persistent intrusive thoughts.

9.

b) Clubfoot may be congenital, teratologic, or
po itional. Examination of the infant clubfoot
demonstrates hindfoot equinus and varus, forefoot
adduction, and variable rigidity.

5.

d) A term used to describe the specific
dysmorphology of the face in which the eyebrows
meet in the miilline.
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10. a) This a Freudian condition which is roughly parallel
to the gender-reversed Oedipal complex; a female
child's morbid attachment to the parent of the
opposite sex, and her jealousy towards the parent of
the same sex.
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At Picker, our Outlook is diHerent.

~UTLOOK
The Outlook system is a new concept in whole
body MR imaging. The economical, C-style
0.23 Tesla, cryogen free electromagnet has a
bigger gap and wider sight lines for greater
patient comfort. The system also features the
latest pha ed array imaging capabilities.
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